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Abstract 
 
The aims of this qualitative descriptive study were to describe the experience of 
chemotherapy-related cognitive impairment (CRCI) for women with breast cancer who 
received chemotherapy; and identify information about CRCI that women would find 
useful prior to chemotherapy and the onset of CRCI. In-depth interviews were conducted 
with 18 women who reported changes in cognitive function and were within 6-12 months 
of completing chemotherapy. Participants described issues with short term memory, 
trouble focusing, and difficulty with word finding, reading, and driving. Support and 
validation of the experience was acknowledged as important. Coping strategies included 
writing things down, depending on others, focusing on one task at a time, and giving 
oneself permission to make mistakes. Participants wanted to receive information about 
CRCI prior to initiating chemotherapy and desired an individualized approach to 
education and made specific recommendations for educational content. On-going 
assessment for CRCI and reinforcement of education were recommended.  
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Chapter I: Introduction 
 
Problem Statement and Study Purpose 
Women with breast cancer complain of a lack of acknowledgement and education 
about the potential for cognitive changes related to chemotherapy.  Cognitive changes can 
have a significant impact on cancer survivors’ quality of life (QOL) and lack of information 
regarding the potential risk for chemotherapy-related cognitive impairment (CRCI) prevents 
obtaining full informed consent prior to initiation of therapy. Lack of acknowledgement of 
CRCI by health care providers (HCPs) is a source of frustration and dissatisfaction to patients 
experiencing cognitive changes. The purpose of this qualitative descriptive study was to 
provide an in-depth description of the patient experience of CRCI for women with breast 
cancer.  
Background & Significance 
CRCI is recognized as a serious potential sequela to treatment for cancer.   Estimates 
of frequency range as high as 75% for patients receiving chemotherapy (Ahles, et al., 2002) 
and from 17-34% two or more years after completion of therapy (Ahles & Saykin, 2007).  
Cognitive impairment  attributed to standard doses of chemotherapy (as opposed to high-dose 
or intrathecal regimens) has only recently been addressed consistently in the literature, 
although some researchers recognized this phenomenon in the late 1970s and early 1980s 
(Ahles & Saykin, 2001; Silberfarb, 1983; Silberfarb, Philibert, & Levine, 1980; Weiss, 
Walker, & Wieneke, 1974).   
 CRCI can have a dramatic effect on survivors’ quality of life (Ahles & Saykin, 2001; 
Tannock, Ahles, Ganz, & van Dam, 2004).  The impact has been recognized by the 
President’s Cancer Panel, the National Coalition for Cancer Survivorship (Reuben, 2004), 
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and the Oncology Nursing Society as a national research priority (Berger, 2009).  
Participants on the President’s Cancer Panel noted that insufficient care may result from 
HCPs failure to acknowledge the problem and may be due in part from a lack of information 
about this treatment-related effect.   
To date, much of the research for CRCI has been conducted in patients with breast 
cancer due to prolonged survival time and patients’ assertiveness in communicating concern 
about cognitive changes (Castellon et al., 2004; Kreukels et al., 2006; O'Shaughnessy, 2003; 
Schagen, Muller, Boogerd, & van Dam, 2002).  Up to 83% of breast cancer survivors who 
received chemotherapy report some degree of cognitive dysfunction (Jenkins, 2006; 
O’Shaughnessy), which is consistent with the overall estimated frequency for patients 
receiving chemotherapy cited above.  Survivors of breast cancer comprise a significant 
portion of the cancer survivor population as breast cancer is the most common malignancy in 
females.  Current estimates of new cases of breast cancer incidence in the United States for 
2010 are 207,090 (American Cancer Society 2010) and five year survival rates for all stages 
of the disease are 90%.  In 2010, 2.9 million breast cancer survivors are predicted in the 
United States (De Angelis, et al., 2009).   
Very little literature exists to describe the patient experience with CRCI, including the 
experience related to the treatment of breast cancer (Boykoff, Moieni, & Subramanian, 2009; 
Mulrooney, 2007; Thielen, 2009; Wagner, Sweet, Butt, Lai, & Cella, 2009).  Few 
educational tools are available and oncology nurses have acknowledged lack of access to 
appropriate patient/family educational materials (Myers & Teel, 2008).  One key aspect of 
the oncology nursing role is patient/family education regarding expected or potential side 
effects of therapy.  A recent pilot study was conducted to evaluate oncology nurses’ 
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awareness of CRCI and to ascertain whether oncology nurses assessed patients for this side 
effect and provided education to patients prior to therapy.  Results from the pilot study 
indicated that 38% of participants assessed patients for CRCI and 71% of participants did not 
have access to related educational materials for CRCI (Myers & Teel).   
Recognition of CRCI as a national research priority and the potential for impact of 
CRCI on quality of life provides the rationale for continued research.  Despite the fact that 
much research has been conducted with breast cancer survivors, significant gaps in the 
literature remain related to the description and meaning of the patient experience and 
practical suggestions for patient education.  Lack of pre-treatment patient education 
contributes to less than comprehensive informed consent. As the experience of CRCI in 
patients with breast cancer becomes well defined, results may be used to begin to explore the 
experience of CRCI in patients with other types of malignancies treated with chemotherapy.   
Chemotherapy-Related Cognitive Impairment 
 Mild cognitive impairment following chemotherapy often is referred to as “chemo 
brain” by the lay public (Matsuda et al., 2005).  Cull, et al. (1996) described CRCI as 
subjective and objective changes in cognitive function related to chemotherapy.  The impact 
of CRCI typically is subtle and is believed to reduce over time.  The specific domains of 
cognitive function that may be affected include executive function, information-processing 
speed, language, motor function, spatial skills, learning, and memory (Jansen, Miaskowski, 
Dodd, Dowling, & Kramer, 2005).  Patients describe the effects on cognitive function as 
forgetfulness, absentmindedness, and an inability to focus when performing daily tasks (Hess 
& Insel, 2007).   
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 A variety of potentially associated factors have been identified, including age, 
education level, intelligence, and social support; anxiety, depression, and fatigue; disease 
site, stage, and comorbidities; treatment regimen, timing, duration, and concomitant 
therapies; hormonal levels, cytokine levels, damage to neural progenitor cells, and the 
presence of the apolipoprotein E 4 allele (Hess & Insel, 2007; Jansen, Miaskowski, Dodd, 
Dowling, & Kramer, 2005).  These factors are acknowledged for the potential to contribute 
to changes in cognitive function.  Further research is needed to describe the relationships 
between these factors and the development and severity of CRCI.  Advancing age has been 
associated with memory problems unrelated to cancer or cancer therapy (Barnes et al., 2003) 
and thus may exacerbate the risk of CRCI.  Recent research indicates that younger age may 
be associated with an increased perception of changes in cognitive function and therefore a 
greater impact on quality of life (Cimprich et al., 2005).  Higher levels of education and 
intelligence are hypothesized to be associated with high baseline function and cognitive 
reserve that may impact the effects of chemotherapy on cognitive performance (Jansen et al, 
2007).  Lack of social support, anxiety, depression, fatigue, and decreased levels of 
circulating estrogen and testosterone may contribute to decreased mental acuity.  The timing, 
intensity and composition of the chemotherapy treatment regimen may contribute to the 
severity of changes in cognitive function (Jansen et al., 2007).   
 The exact etiology of CRCI is not known, but a number of etiologies have been 
proposed, including direct injury to cerebral gray and white matter, microvascular injury 
(Wefel et al., 2004), DNA damage and oxidative stress (Ahles & Saykin, 2007; Chen, 
Jungsuwadee, Vore, Butterfield, & St. Clair, 2007), cytokine-induced inflammatory response 
(Ahles & Saykin, 2007), chemotherapy-induced anemia (Mancuso, Migliorino, De Santis, 
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Saponiero, & De Marinis, 2006; Massa, Madeddu, Lusso, Gramignano, & Mantovani, 2006), 
and chemotherapy-induced menopause (Jansen, Miaskowski, Dodd, & Dowling, 2005).  
Recent preclinical investigation has highlighted a potential relationship between injury to 
neural progenitor cells (NPCs), impaired maintenance of white matter integrity, and 
subsequent cognitive impairment (Dietrich, Han, Yang, Mayer-Proschel, & Noble, 2006; 
Dietrich, Monje, Wefel, & Meyers, 2008; Han, et al., 2008).  Dietrich, Han, et al. noted that 
self-renewing, lineage-committed NPCs and nondividing mature oligodendrocytes (myelin-
forming cells) are the most vulnerable cell populations to chemotherapeutic agents.  
Repetitive exposure to chemotherapeutic agents exceeded cellular repair potential and 
resulted in long-term suppression of cell division and apoptosis in the subventricular zone, 
hippocampus, and major white matter tracts of the CNS in animal models.  Animal modeling 
work provides the basis for further research to attribute causality to specific chemotherapy 
agents or combinations to areas of the brain important to cognitive performance and 
executive function. 
 Secondary inflammatory response has been related to the sickness behavior seen with 
proinflammatory cytokine release.  Some understanding of the role of cytokines in induction 
of sickness behavior evolved from observing the side effects experienced by patients with 
cancer receiving treatment with immunomodulating agents, such as interferon alpha, tumor 
necrosis factor and interleukin-2.  The side effect called “flu-like syndrome” is comprised of 
the same characteristics seen with sickness behavior (De La Garza, 2005).  Patients exhibit 
fever, chills, lethargy, anorexia, and cognitive impairment.  Rationale for the cognitive 
impairment seen in conjunction with the release and exogenous administration of cytokines is 
emerging.  Chemotherapy-induced side effects are similar to those seen in the sickness 
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behavior attributed to proinflammatory cytokine release (Wood, Nail, Gilster, Winters, & 
Elesea, 2006).  A variety of antineoplastic agents induce production of proinflammatory 
cytokines in various cell lines in vitro (Maier & Watkins, 2003; Niiya et al., 2003; 
Wichmann, et al., 2003; Zaks-Zilberman, Zaks, & Vogel, 2001).  The taxanes (paclitaxel and 
docetaxel) have been associated with increased plasma levels of interleukins 6, 8, and 10 
(Ahles & Saykin, 2007).   
 Oxidative stress occurs when the generation of reactive oxygen and nitrogen species 
exceed cellular adaptive and repair capacities (Chen et al., 2007).  Antineoplastic agents used 
to treat breast cancer that have been reported to induce oxidative stress include the 
anthracyclines, cyclophosphamide, and fluorouracil.   
 Oxidative stress associated with doxorubicin therapy (an anthracycline) occurs in 
nontargeted tissues and leads to injury of normal tissues (Chen et al., 2007).  Doxorubicin, 
like other chemotherapy agents administered in standard doses, was believed not to cross the 
blood brain barrier.  However, doxorubicin has been associated with increased circulating 
levels of tumor necrosis factor alpha (TNF-α) in animal models.  TNF-α can penetrate the 
blood-brain barrier and activate glial cells in the central nervous system (CNS) to further 
TNF-α production in the brain.  The synthesis of TNF-α in the CNS is related to the 
induction of nitric oxide synthase (Chen et al.).  As a result, the generation of reactive 
nitrogen species, including nitric oxide, increases (Tangpong et al., 2007).  In addition, the 
neurotoxicity associated with doxorubicin-induced TNF-α resembles the free radical 
mechanisms implicated in Alzheimer’s disease (Tangpong et al.).   
 The presence of the apolipoprotein (APOE) E4 allele may predispose patients to 
cognitive impairment (Ahles & Saykin, 2002; Ahles et al., 2003).  APOE is “a complex 
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glycolipoprotein that facilitates the uptake, transport and distribution of lipids” and appears 
to have a role in neuronal repair after injury (Ahles & Saykin, 2007, p. 198).  The E4 allele is 
associated with Alzheimer’s disease and poor recovery from stroke and traumatic brain 
injury.  Some prospective trials to evaluate CRCI now include genetic measurements to 
assess whether a genetic predisposition to more significant and longer-lasting injury from 
chemotherapy exists (Ahles & Saykin, 2007).  Those prospective trials may help answer the 
question of whether some patients are genetically predisposed to long-term damage, and 
results could have significant impact on treatment options for cancer.  
Chemotherapy for Breast Cancer 
 The decision to offer adjuvant chemotherapy to women diagnosed with non-
metastatic invasive breast cancer (stages I-III) is based on a number of factors associated 
with the risk of recurrence.  Primary considerations include tumor size, hormone receptor 
status, lymph node status, and tumor grade (NCI, 2009a). Women at intermediate or high risk 
of recurrence typically are offered adjuvant chemotherapy.  Combination chemotherapy and 
hormonal therapy (with selective estrogen receptor modulators or aromatase inhibitors) is 
common for women who are estrogen receptor (ER) and/or progestin receptor (PR) positive.  
Women with over-expression of the human epidermal growth factor receptor two (HER-2) 
neu oncogene also are offered treatment with the anti-HER-2 monoclonal antibody, 
trastuzumab.  Data related to treatment efficacy are limited for women over the age of 70 
years as many clinical trials exclude the elderly due to the presence of comorbidities and 
reductions in performance status.   
The National Coalition of Cancer Survivors publishes evidence-based treatment 
guidelines for the treatment of breast cancer (NCCN, 2009).  Numerous chemotherapy 
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regimens are listed as preferred (category 1 level of evidence).  Most of these regimens 
contain an anthracycline (doxorubicin), cyclophosphamide, and a taxane (docetaxel or 
paclitaxel).  Many of the older regimens, no longer listed as category 1, contain fluorouracil 
and methotrexate.  As mentioned above, the anthracyclines, cycophosphamide, and 
fluorouracil are associated with oxidative stress.  Taxanes are associated with the release of 
proinflammatory cytokines and known to cause peripheral neuropathies.  Methotrexate has 
been associated with neurotoxicity in studies done to evaluate CRCI (Scherwath et al., 2006; 
Tchen et al., 2003).     
Challenges with Neurocognitive Testing 
Standard neurocognitive tests have been developed to evaluate cognitive performance 
across domains such as attention and concentration, executive function, information-
processing speed, language, motor function, visuospatial skill, learning and memory (Jansen, 
Miaskowski, Dodd, Dowling, & Kramer, 2005).  A number of these tests have been shown to 
have some sensitivity to CRCI in patients with breast cancer. Jansen et al. (2007) conducted a 
meta-analysis of the various neurocognitive tests used to detect CRCI in patients with breast 
cancer.  They reviewed 13 studies and utilized meta-analysis software to calculate 
standardized mean difference effect size and a 95% confidence interval.  Effect sizes were 
interpreted as negligible (< 0.20), small (.20-.50), medium (.50-.80) and large (greater than 
.80).  Tests that were used in at least two or more studies were included in the analysis and 
30 tests were examined.  Only 6 of the tests were sensitive to CRCI in 4 of the 8 cognitive 
domains (language, motor function, visuospatial skill, and verbal memory) (see Table 1).  
The authors noted that “most of the neurocognitive tests used in the studies performed to date 
do not appear to be sensitive enough to detect changes in cognitive function” (p. 1004).  
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Table 1 
Neurocognitive Tests Shown to be Sensitive to CRCI in Patients with Breast Cancer 
 
Domain  Test     Effect Size 
 
Language  HSCS Language Subtest  Small 
Motor Function Grooved Pegboard   Large 
   Fepsy Finger Tapping Test  Moderate 
Visuospatial skill RCFT Copy Test   Moderate 
   WAIS Block Design Subtest  Moderate  
Verbal Memory HSCS Memory Subtest  Small 
HSCS = High Sensitivity Cognitive Screen, RCFT = Rey-Osterrieth Complex Figure Test, 
WAIS = Wechsler Adult Intelligence Scale 
Adapted from Jansen et al., 2007. 
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Learning and memory sometimes is divided into visual and verbal memory (Nail, 
2006).  Abstract reasoning also is periodically assessed as a component of neurocognitive 
testing (Freeman & Broshek, 2002).  Results provide insight into specific areas of brain 
injury based on individuals’ performance on tests designed to elicit objective data related to 
the specific cognitive domains (see Table 2) (Ahles &  Saykin, 2007; Jansen, Miaskowski, 
Dodd, & Dowling, 2007).   
A number of challenges exist related to neurocognitive testing for CRCI.  One of the 
major challenges is the selection of appropriate assessment tools.  Cognitive changes 
observed in this patient population are subtle.  Tests designed to assess gross changes in 
neurocognitive function associated with severe dementia or head injury are not appropriate 
for patients experiencing CRCI.  Patients who are well educated with high baseline cognitive 
function may continue to score normally on neurocognitive tests, even though they perceive 
deficits that interfere with their daily function and quality of life (Wefel, Lenzi, Theriault, 
Davis, & Meyers, 2004).  The Mini-Mental State Examination (MMSE) has been criticized 
for those reasons (Meyers & Wefel, 2003).  At best, the MMSE may be used as a baseline 
screen to exclude patients from a prospective trial who have significant cognitive deficits 
prior to the initiation of therapy. 
 The array of neurocognitive tests that would normally be employed to conduct a full 
cognitive assessment may range in length from four to seven hours (Freeman & Broshek, 
2002).  Patient burden should be a consideration in determining the extent of testing that 
occurs in each session.  An additional challenge exists for patients experiencing the fatigue 
associated with a cancer diagnosis and treatment (Butt et al., 2008).  Several hours of testing 
may not be practical. In addition, in the context of a clinical trial, the time and expense  
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Table 2 
Domains of Cognitive Function: Corresponding Components and Brain Anatomy 
 
Cognitive Domain Definition    Components   Associated Anatomy 
 
Attention &  Enable ability to triage relevant Arousal   Ascending reticular activating system 
Concentration  inputs, thoughts, and actions  Selective attention  Frontal subcortical network  
   while ignoring those that  Sustained attention or  Rt hemispheric prefrontal and parietal 
   distract or are irrelevant.   vigilance   regions 
   Ability to focus and sustain  Directed attention  Prefrontal cortex (cingulated cortex, 
   attention.          amydgala) 
 
 
Executive Function Higher order cognitive  Initiation   Anterior cingulated cortex 
   Processes that include   Planning   Dorsolateral prefrontal cortex 
   Initiation, planning, hypotheses Cognitive flexibility 
   generation, cognitive flexibility, Self-monitoring 
   decision making, self-   Self-regulation 
   regulation, judgment, 
   feedback utilization, and self- 
   perception.  
 
Information-  Ability to rapidly process  Parietal and frontal lobes 
Processing speed simple and complex 
   information. Linked to all other 
   cognitive domains due to 
   tactile, auditory, verbal and 
   visual nature of input. 
 
Language  Ability to comprehend and  Verbal or written   Supplementary, motor, prefrontal cortices 
   communicate written and   expression  
   spoken symbolic information  Reception   Wernicke’s area 
        Repetition   Broca’s area 
 
Motor function Performance related to speed,  Speed    Frontal lobe (premotor and primary motor) 
   strength, and coordination.  Strength   areas), parital lobe (somatosensory areas), 
        Coordination   cerebellum, brain stem. 
        Dexterity 
        Apraxia     
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Table 2 continued 
 
 
Cognitive Domain Definition    Components   Associated Anatomy 
 
Visuospatial skill Ability to process and interpret Perception   Primary visual cortex in posterior occipital 
   visual information regarding  Construction   lobe, temporal lobes, parietal lobes 
   where things are situated in   
   space.      
 
Learning and   Ability to acquire, store, and  Learning 
Memory  access new information  Short-term memory  Reticular activating system, dorsolateral 
            prefrontal cortex, parietal cortex, medial 
            temporal lobe, amygdale, orbitofrontal 
            cortex 
 
        Long-term memory  Frontal and anterior temporal lobes 
        Recall    Prefrontal cortex 
        Recognition 
        Verbal memory  Left hemisphere 
        Visual memory  Right hemisphere 
 
 
 
 
Ahles & Saykin 2007; Freeman 2002; Jansen et al. 2005, 2007 
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involved in extensive testing may preclude a complete examination from being included in 
the protocol (Freeman & Broshek).  A multidisciplinary workshop held in 2004 yielded the 
suggestion of a two-stage approach to cognitive assessment, depending on the question that 
was being asked (Tannock et al., 2004).  When the goal is demonstration of a cognitive 
change in a large sample of patients in a clinical trial, brief validated assessment such as the 
Functional Assessment of Cancer Therapy-Cognitive Function scale (FACT-COG, a self-
report measure) (Wagner, et al, 2009) may be appropriate (stage 1).  Workshop participants 
acknowledged that most brief measures do not have sensitivity for impaired executive 
function and therefore might lead to underreporting of deficits.  Patients who demonstrate a 
change in cognitive function by brief objective assessment can then be referred for more 
thorough evaluation with conventional neurocognitive testing (stage 2) (Tannock et al.).   
 Studies conducted to date have employed a variety of different neurocognitive tests to 
evaluate cognitive function.  For results to be compared, the use of consistent tests would be 
very advantageous.  One of the recommendations of the multidisciplinary workshop was to 
identify tests sensitive to the subtle changes observed with CRCI as well as to develop and 
validate self-report forms (Tannock et al.).  As important as objective tests of cognitive 
function are, patient perception of cognitive function and the resultant impact on QOL 
remain important aspects of the assessment process (Minisini, et al., 2004).   
 Additional challenges of the current process of neurocognitive testing for patients 
experiencing CRCI revolve around the difficulty in replication of a real-life situation.  
Typically, neurocognitive testing occurs in a laboratory-like environment that has little 
overlap with a patients’ everyday experience (Schagen, et al., 2002).  Current testing 
procedures are criticized for low ecologic relevance and sterile conditions with minimal 
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distraction.  Patients with cancer who self-report CRCI describe an inability to multitask, 
which is difficult to replicate in a testing situation (Cimprich, So, Ronis, & Trask, 2005).   
 Assessment of cognitive function in participants with cancer is further complicated by 
a number of potentially confounding variables such as age, education, hormonal status, 
anemia, fatigue, anxiety, and depression (Nail, 2006).  Controlling for these factors still 
yields the independent presence of cognitive change in patients who have received 
chemotherapy (Ahles et al., 2002).  However age and education are significant predictors of 
cognitive performance.  More years of education have been associated with better 
performance on measures of cognitive function (Cimprich, et al., 2005).  Cimprich et al. 
(2005) studied pre-treatment factors related to cognitive functioning in newly diagnosed 
women with breast cancer.  Cimprich noted that younger women may have perceived even 
small fatigue-related losses in attention that interfered with usual levels of functioning but 
were not detectable on testing.  Older women demonstrated decreased ability to direct 
attention prior to any treatment and thus may be at higher risk for treatment-related changes 
in cognitive function.  Cimprich also noted that depression is positively correlated with 
patients’ self-report of cognitive changes.  Hypotheses generated about the discrepancy 
between self-report and objective testing include the rationale that subjective measures 
reflect perceived changes while objective measures only assess current performance and do 
not reflect changes over time.  Thus subjective measures may be sensitive to smaller effect 
sizes than those of objective measures available today (Jacobs, Jacobsen, Booth-Jones, 
Wagner, & Anasetti, 2007).   
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Importance of Self-Report 
Substantive work remains to be done to identify the neurocognitive tests most 
sensitive to CRCI and to develop new tests more closely related to real-life situations where 
cognitive changes are noted (Ahles & Saykin, 2007).  The importance of assessing patients’ 
perceptions of cognitive change cannot be ignored (O'Shaughnessy, 2003).  Patients’ self-
report of perceptions of cognitive change may be more sensitive to subtle deficits in function 
than standard neurocognitive tests (Schagen, et al., 2002).  Researchers are beginning to 
advocate the position that patient-reported cognitive function is an important endpoint in its 
own right due to the profound impact of perceived cognitive function on QOL and evidence 
of an association between patient-reported cognitive decline and with increased cognitive 
effort demonstrated by neuroimaging (Ferguson, McDonald, Saykin, & Ahles, 2007; Lai, et 
al., 2009; Saykin, et al., 2006; Scherwath, et al., 2006; Wagner, et al.).   
Patients’ description of the lived experience of CRCI may provide rich data that are 
useful in more accurately defining the types of cognitive changes that result from 
chemotherapy.  Ahles and  Saykin (2001) noted that the use of quantitative instruments may 
obtain data less rich in describing the cancer experience.  They offered the example of 
comparing responses to a quantitative survey with questions about the impact of 
chemotherapy on job performance.  Use of the quantitative survey yielded the information 
that a patient was able to work in the same profession following chemotherapy.  Results of 
the qualitative assessment indicated that while the patient may have remained in the same 
profession, the decision was made to move to a less demanding position or not to compete 
for a promotion due to impairment of cognitive function (Ahles & Saykin, 2001).  Work-
related limitations may contribute to additional impact on QOL. 
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 CRCI can have a dramatic effect on survivors’ quality of life, such as changes in the 
ability to maintain a job/role, participate in enjoyable activities and have an absence of 
distress (Ahles & Saykin, 2001; Boykoff et al., 2009; Tannock et al., 2004).  Patients have 
expressed concern about CRCI and their subsequent ability to resume previous professional, 
scholastic, and social activities (Wefel et al., 2004). No data are available on the percentage 
of patients who miss or lose work because of this adverse event.  Estimating the cost of CRCI 
is difficult because prospective trials to ascertain a more precise incidence, risk factors and 
specific impact on quality of life are ongoing.  CRCI is a significant concern because of the 
prevalence of the symptom experience and patients’ concerns about the impact on QOL.  
Given the significance of CRCI to patients, appropriate measures should be taken to educate 
patients and families about the potential for CRCI, assess and diagnose the CRCI, and 
recommend interventions to assist patients in coping with changes in function they 
experience. 
Study Purpose and Aims 
 The purpose of this qualitative descriptive study was to provide an in-depth 
description of the experience of CRCI for women with breast cancer.  Specific aims of the 
study were to: 1) Describe the experience of CRCI for women with breast cancer who have 
received chemotherapy treatments; and 2) Identify information about CRCI that women 
would find useful prior to initiation of chemotherapy and following the onset of CRCI . 
Research Questions  
 The study was designed to answer the following research questions: 1) How do 
women who have received chemotherapy for breast cancer describe the experience of 
CRCI?; 2) What information about CRCI would women who have received chemotherapy 
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for breast cancer have found helpful prior to initiation of treatment?; and 3) What 
information about CRCI would women with breast cancer have found helpful once changes 
in cognition are experienced?  
 Outcomes 
 Information gleaned from this study adds to the body of knowledge related to the 
experience of CRCI from the patients’ perspective by providing a comprehensive description 
of the phenomenon.  Participants’ descriptions of information they would have found helpful 
prior to therapy and after experiencing cognitive changes will be used to support the 
development of appropriate educational tools. Enhanced understanding of CRCI by 
oncologists and oncology nurses and appropriate patient/family education is necessary to 
obtain full informed consent prior to initiating chemotherapy.  Recognition and 
acknowledgement of CRCI by HCPs and pre-treatment education will decrease frustration 
and dissatisfaction for women with breast cancer.  A deeper understanding of the patient 
experience with CRCI may lead to refinement of existing or development of more sensitive, 
neurocognitive tests to measure CRCI.  As the experience of CRCI in patents with breast 
cancer becomes better defined, the knowledge may be used to begin to explore the 
experience of CRCI in patients with other types of malignancies treated with chemotherapy.  
Summary 
 CRCI is estimated to occur in up to 83% of patients with breast cancer and has been 
identified as a national research priority.  Mechanisms of causality remain unclear as do the 
specific relationships with potentially confounding and/or exacerbating factors.  No standard 
for assessment has been determined. A number of issues relate to the lack of sensitivity of 
current objective methods to measure cognitive function in this patient population.  Self-
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report is gaining favor as the most sensitive measure of the subtle changes in cognitive 
function experienced in conjunction with chemotherapy.   
Very little literature exists to describe the patient experience.  Patients’ descriptions 
of their perceptions of the phenomenon are necessary for providing appropriate education, 
revising current neurocognitive tests to achieve more ecologic validity or developing new 
tests that are more sensitive to the subtleties of CRCI.  The following chapter includes a 
review of literature pertinent to this study.  Gaps in the literature are identified in support of 
the research questions and hypotheses. 
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Chapter 2: Review of Literature 
 The review of the literature begins with an overview of studies conducted to 
demonstrate evidence of CRCI in patients with breast cancer.  A review of work done to 
evaluate the timing of the occurrence of CRCI as a late effect of chemotherapy as well as 
comparisons of dose intensity follows.  Exploration of the potential for hormonal influence 
such as decreased estradiol levels associated with both treatment-induced menopause and 
aromatase inhibition is reviewed.  Hormone levels potentially are confounding factors for 
changes in cognitive function as a normal part of the aging process.  A summary of 
neurocognitive tests and self-report measures used for each of the studies reviewed are noted 
in Table 3.  The volume and variety of neurocognitive testing demonstrates the lack of 
standardization or agreement as to the best objective measures of cognitive function for 
patients who have received chemotherapy.  Study results supporting the role for patients’ 
self-report of CRCI as a valid measure are discussed.  A summary of contradictory findings 
is provided.  Results of relevant qualitative research performed to describe the patient 
experience of CRCI and patients’ need for acknowledgement and education are reviewed. 
This chapter concludes with a summary of gaps in previous research lending support for this 
research proposal. 
Evidence for CRCI in Breast Cancer 
 Early work related to the quest for objective evidence for chemotherapy-related 
deterioration in cognitive function for women treated for breast cancer was published by 
Wieneke and Dienst (1995).  They evaluated 28 women (ages 28-54) with early stage disease 
(I, II) who had no evidence of metastases or comorbidities and were treated with standard-
dose chemotherapy: cyclophosphamide, doxorubicin, and fluorouracil (CAF) and/or  
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Table 3 
 
Summary of Neurocognitive Tests and Self-Report Measures 
 
 
Reference & Title    Neurocognitive tests    Self-Report Measures 
 
 
Ahles & Saykin, 2002   Wechsler Adult Intelligence Scale III Squire Memory Self-Rating Questionnaire 
 Neuropsychologic impact of   Vocabulary    Center for Epidemiological Study  
 standard-dose systemic  Wide Range Achievement Reading   Depression Scale 
 Chemotherapy in long-term   Subtest    Spielberger State-Trait Anxiety Inventory 
 Survivors of breast cancer and California Verbal Learning 
 Lymphoma    Wechsler Memory Scale Revised 
       Logical Memory  
       Verbal Memory 
      Finger Tapping and Thumb-Finger 
       Sequencing 
      Continuous Performance Vigilance 
       and Distractibility Subtests 
 
Bender et al., 2006 
 Cognitive impairment   Digit Vigilance 
 associated with adjuvant  Trail Making 
 therapy in breast cancer  Rey Auditory Verbal Learning 
      Rey Osterrieth Complex Figure 
      Four Word Short Memory 
 
 
  
 
Bender et al., 2007 
 Memory impairments with  Digit Span     Beck Depression Inventory 
 adjuvant anastrozole versus  Digit Vigilance    Profile of Mood States Tension/Anxiety 
 tamoxifen in women with early- Rey Auditory Verbal Learning   Subscale 
 stage breast cancer   Rivermead Behavioral Memory 
      Rey Osterrieth Complex Figure   
      Grooved Pegboard    
      National Adult Reading-Revised 
 
Brezden et al., 2000   
 Cognitive function in breast  High Sensitivity Cognitive Screen  Profile of Mood States  
 cancer patients receiving 
 adjuvant chemotherapy 
  
Castellon et al., 2004 
 Neurocognitive performance  Controlled Oral Word Association  Beck Depression Inventory 
 in breast cancer survivors  California Verbal Learning   Spielberger State-Trait Anxiety 
 exposed to adjuvant   Wechsler Memory Scale Logical   Inventory 
 chemotherapy and tamoxifen   Memory and Visual Repro-  Medical Outcomes Study Short Form-36 
       duction 
      Wechsler Adult Intelligence Scale 
       Digit Symbol 
      Rey Osterrieth Complex Figure 
      California Computerized Assessment 
       Package 
      Paced Auditory Serial Additional  
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Table 3 continued 
 
 
Reference & Title    Neurocognitive tests    Self-Report Measures 
 
 
Cimprich & Ronis, 2001   Mini-Mental State Exam   Symptom Distress Scale 
 Attention and symptom  Digit Span     Profile of Mood States Depression Subscale
 distress in women with and  Symbol Digit Modalities 
 without breast cancer   Necker Cube Pattern Control 
 
Cimprich et al., 2005  
 Pre-treatment factors related  Digit Span     Attentional Functional Index  
 to cognitive functioning in  Trail Making Test    Symptom Distress Scale 
 women newly diagnosed with Three Shapes Three Words   Profile of Mood States 
 breast cancer  
 
Downie et al., 2006 
 Cognitive function, fatigue  High Sensitivity Cognitive Screen  Functional Assessment of Cancer Therapy- 
 and menopausal symptoms in        General, Fatigue, Endocrine  
 breast cancer patients receiving        Symptoms 
 adjuvant chemotherapy:  
 Evaluation with patient interview 
 after formal assessment 
 
Jenkins et al., 2006 
 A 3-year prospective study of Wechsler Memory Scale-III   General Health Questionnaire 
 the effects of adjuvant treatments National Adult Reading    Broadbent Cognitive Failures 
 on cognition in women with early        Questionnaire 
 stage breast cancer   Wechsler Adult Intelligence Scale  Functional Assessment of Cancer Therapy- 
      Rey Osterrieth Complex Figure   Questionnaires for Breast, Fatigue 
      Stroop       and Endocrine Symptoms 
      Digit Span 
      Letter Cancellation 
      Spatial Span 
      Letter/Number sequencing 
  
 
Jenkins et al., 2004 
 Does hormone therapy for the Wechsler Memory Scale-III   Beck Depression Inventory 
 treatment of breast cancer   Verbal Memory,   General Health Questionnaire 
 have a detrimental effect on   Visual Memory,   Cognitive Failure Questionnaire 
 cognition? A pilot study   Working Memory 
 
Klemp et al., 2006 
 Evaluating the effects of  High Sensitivity Cognitive Screen  Cognitive Difficulties Scale 
 chemotherapy on cognitive        RAND 36-Item Health Survey 
 function and quality of life in        Breast Cancer Prevention Trial Symptom 
 pre-menopausal women with         Check List 
 breast cancer          Beck Depression Inventory 
            Center for Epidemiological Studies  
             Depression Scale   
            Functional Assessment of Cancer Therapy- 
             Anemia 
 
  
Mar Fan et al., 2005 
 Fatigue menopausal symptoms High Sensitivity Cognitive Screen  Functional Assessment of Cancer Therapy 
 and cognitive function in women Mini-Mental State Exam    Questionnaires for Breast, Fatigue  
 after adjuvant chemotherapy for Conner’s Continuous Performance   and Endocrine Symptoms  
 breast cancer: 1- and 2-year  Trail-Making 
 follow-up of a prospective 
 controlled study.  
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Table 3 continued 
 
 
Reference & Title    Neurocognitive tests    Self-Report Measures 
 
  
Paganini-Hill & Clark, 2000 
 Preliminary assessment of  Clock Drawing Task    Geriatric Depression Scale 
 cognitive function in breast  Necker Cube 
 cancer patients treated with  Narrative Task 
 tamoxifen  
 
Schagen et al., 1999 
 Cognitive deficits after  Rey Auditory Verbal Learning  Hopkin’s Symptom Checklist 
 postoperative chemotherapy  Complex Figure    European Organization for Research and 
 for breast carcinoma   Digit Span      Treatment of Cancer Quality of Life 
      Digit Symbol      Questionnaire-30 
      Trail Making 
      D2 
      Stroop 
      Dutch Aphasia Society Word 
       Fluency Subtest 
      Fepsy Finger Tapping 
      Fepsy Visual Reaction 
      Fepsy Binary Choice 
      Fepsy Visual Searching 
      Dutch Adult Reading 
 
Schagen et al., 2002    Same as above 
  
 
Scherwath et al., 2006 
 Neuropsychological function  Trail Making 
 in high-risk breast cancer  Test Battery for Attentional Performance 
 survivors after stem-cell  Test d2 Cancellation 
 supported high-dose therapy  Wechsler Memory Scale-Revised 
 versus standard-dose   Rey-Osterrieth Complex Figure 
 chemotherapy: Evaluation of  Regensburger Wortflussigkeits 
 long-term effects   Leistungsprufsystem Achievement 
       Measure System 
      Hamburg-Wechsler Intelligence Scale- 
       Revised  
Shilling et al., 2003 
 The effects of hormone  Wechsler Memory Scale-III   Beck Depression Inventory 
 therapy on cognition in breast  Verbal Memory, Visual Memory General Health Questionnaire 
 cancer      Working Memory   Cognitive Failure Questionnaire 
 
Tchen et al., 2003 
 Cognitive function, fatigue  High Sensitivity Cognitive Screen  Functional Assessment of Cancer Therapy 
 and menopausal symptoms in  Mini Mental State Exam   Questionnaires for Breast, Fatigue 
 women receiving adjuvant  Conner’s Continuous Performance   and Endocrine Symptoms 
 chemotherapy for breast cancer Trail-Making  
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Table 3 continued 
 
 
Reference & Title    Neurocognitive tests    Self-Report Measures 
 
 
van Dam et al., 1998 
 Impairment of cognitive function Rey Auditory Verbal Learning  Hopkin’s Symptom Checklist 
 in women receiving adjuvant  Complex Figure     European Organization for Research and 
 treatment for high-risk breast  Digit Span      Treatment of Cancer Qualtiy of Life
 cancer: High-dose versus   Digit Symbol      Questionnaire-30 
 standard-dose chemotherapy  Trail Making 
      D2 
      Stroop 
      Dutch Aphasia Society Word 
       Fluency Subtest 
      Fepsy Finger Tapping 
      Fepsy Visual Reaction 
      Fepsy Binary Choice 
      Fepsy Visual Searching 
      Dutch Adult Reading 
 
Von Ah et al., 2009 
 Cognitive function in breast  Auditory Verbal Learning   Center for Epidemiological Studies  
 cancer survivors compared to  Digit Span      Depression Scale 
 healthy-age and education-  Digit Symbol     Squire Memory Self-Report 
 matched women   Controlled Oral Word Association 
  
 
Wefel et al., 2004 
 The cognitive sequelae of  Wechsler Adult Intelligence Scale  Functional Assessment of Cancer Therapy- 
 standard-dose adjuvant   Revised Digit Span, Digit   Breast 
 chemotherapy in women with  Symbol, Similarities, Block 
 Breast cancer     Design 
      Trail Making 
      Verbal Selective Reminding 
      Nonverbal Selective Reminding 
      Multilingual Aphasia Examination 
       Controlled Oral Word 
       Association 
      Booklet Category 
 
Wieneke & Dienst, 1995 
 Neuropsychological   Weschler Adult Intelligence Scale  Beck Depression Inventory 
 assessment of cognitive   Intelligence Quotient 
 functioning following   National Adult Reading 
 chemotherapy for breast  Digit Span/Digit Symbol 
 cancer     Paced Auditory Serial Addition 
      Trail Making 
      California Verbal Learning 
      Rey Osterrieth Complex Figure 
      Block Design 
      Grooved Pegboard  
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cychophosphamide, methotrexate, and fluorouracil (CMF) within the previous 12 months.  
Some participants also received hormonal therapy with tamoxifen.  Chemotherapy must have 
been completed at least two weeks prior to neurocognitive testing and participants were 
excluded for history of neurological disorder, serious head injury, psychiatric illness, 
substance abuse, or concomitant medications known to affect cognitive function.  
Participants were evaluated for cognitive performance across nine domains: attention and 
concentration, verbal and visual memory, abstract conceptualization, mental flexibility and 
processing speed, visuospatial ability, motor function, estimated premorbid intelligence and 
depression.  In this study, 75% of women treated with chemotherapy scored within the range 
of moderate cognitive impairment.  The majority of the sample had some college education 
(93%) and 86% (n = 24) received CMF.  Tamoxifen was received by 39% (n = 11).  The 
mean time since completion of chemotherapy was six months.  No significant differences 
were attributed to time since treatment, type of regimen received, or depression.  Study 
limitations included small sample size, retrospective design, and the potential for over 
inclusion of participants who had already voiced cognitive complaints, thus creating a sample 
bias. 
 A similar study was conducted by Brezden et al. (2000). Three groups were 
evaluated: participants currently receiving cyclophosphamide, epirubicin, and fluorouracil 
(CEF) or CMF for at least two cycles (Group A), participants who had completed 
chemotherapy at least one year ago who were without disease recurrence (Group B) and 
healthy controls (Group C).  Participants were aged 25-70 years and had no history of gross 
cognitive dysfunction, psychiatric illness, and drug or alcohol abuse.  Six cognitive domains 
were tested: memory, language, visuomotor, spatial, attention and concentration, and 
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executive function.  Participants also were assessed for mood, including anxiety and 
depression.  The sample consisted of 107 women (Group A: n = 31, Group B: n = 40, Group 
C: n = 36).  Sixteen women in Group B were currently taking tamoxifen and two women had 
taken tamoxifen previously.  Significant differences in cognitive function were seen between 
those currently receiving chemotherapy (Group A) and healthy controls (Group C) (p = 
.009).  Analysis of covariance was used to examine the impact of age, education level, and 
menopausal status.  The significance of the difference between Group A and Group C did not 
change.  No significant differences were seen between participants receiving FEC versus 
CMF.   
Efforts continue to define the incidence and risk factors for CRCI.  Von Ah, 
Harvison, Carpenter, and Unversagt (2009) examined cognitive function in breast cancer 
survivors (n = 52) compared to age-and-education matched healthy controls (n = 52) through 
a cross-sectional, case-control design.  Neurocognitive testing was conducted in person or 
over the phone for the following domains: short and long-term memory, attention, 
concentration, working memory, executive function, language, processing speed, and self-
report of mood and memory.  Eligible participants were >40 years of age, >1 year post 
chemotherapy, and without evidence of major medical, neurologic, or psychiatric illness, 
head injury, epilepsy, stroke, brain tumors/infection/degeneration.  Statistical testing 
controlled for age, education, format of test administration (in person versus phone), 
hormonal therapy, and time since completion of chemotherapy.  Breast cancer (BC) survivors 
had clinically significant impairment in one or more cognitive tests (36%).  BC survivors less 
than 4 years after completion of chemotherapy scored significantly lower on tests for delayed 
recall.  
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Dose Intensity and Timing of CRCI 
Late effects of chemotherapy are of interest due to the potential for impact on quality 
of life for cancer survivors.  Schagen et al. (1999) evaluated 39 women with breast cancer to 
examine the late effects of cyclophosphamide, methotrexate, and fluorouracil (CMF) on 
cognitive function.  Twenty participants completed six courses of CMF followed by 3 years 
of hormonal therapy with tamoxifen.  Nineteen did not receive hormonal therapy.  Age-
matched, lymph node negative breast cancer patients who did not receive systemic adjuvant 
therapy served as controls (n = 34).  Eligible participants were free of relapse or metastatic 
disease and must have been at least six months post completion of chemotherapy.  
Participants were excluded for history of neurologic or psychiatric illness, concomitant 
medications that might affect neurocognitive testing (such as benzodiazepenes or anti-
depressants), alcohol or drug abuse.  Neurocognitive testing was conducted almost two years 
following chemotherapy (mean = 1.9 years) and slightly over two years following local 
therapy for the controls (mean = 2.4 years).  An array of 14 tests was used to evaluate the 
domains of verbal function, memory, attention/concentration, information processing speed, 
motor function, visuocontructional function, and mental flexibility.  Participants also were 
asked to rank the extent of impact experienced in daily life as a component of semi-
structured interviews.  Quality of life (QOL), anxiety and depression also were measured.  
Additional variables entered into multivariate stepwise logistic regression analysis included 
age, intelligence quotient, time since treatment and fatigue.  Problems with concentration 
were reported by 31% of the participants who received chemotherapy and 21% reported 
problems with memory, both of which were significantly higher than the controls (p = 007, p 
= .022).  QOL for physical and cognitive functioning scales also were significantly lower 
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than controls (p = .035, p = .01).  Twenty-eight percent of participants who received 
chemotherapy demonstrated cognitive impairment compared to 12% of controls.  Age, time 
since treatment, anxiety, depression and fatigue did not significantly contribute to the 
regression model.  The risk for cognitive impairment in the chemotherapy group was highly 
increased (p = .013).  No correlation was seen between self-report of cognitive changes and 
objective measures.  However, there was a correlation between the self-report of cognitive 
changes, anxiety, depression, and QOL. The risk for objective changes in cognitive function 
was not affected by anxiety, depression, fatigue, or time since chemotherapy.  In this study, 
no differences were seen in the patients who were treated with tamoxifen. 
 Schagen et al. (2002) continued their previous work in this area by conducting a study 
to evaluate cognitive function in women with breast cancer who were four years post 
chemotherapy.  Participants from two earlier studies (described in the two previous 
paragraphs) were considered eligible if they were free of recurrence (Schagen, et al., 1999; 
van Dam, et al., 1998) and at least one year had passed from the previous neurocognitive 
assessment.  Participants had received high-dose cyclophosphamide, thiotepa, and 
carboplatin (CTC, n = 22), standard-dose fluorouracil, epirubicin, and cyclophosphamide 
(FEC, n = 23) or conventional cyclophosphamide, methotrexate, and fluorouracil (CMF, n = 
27).  Participants were compared to 27 healthy controls.  Eligible participants from the study 
described above and participants from an earlier study (van Dam et al., 1998) were included 
in a follow-up study.  The same measures described above were used in the follow-up study.  
At the time of the follow-up assessment, no significant differences were seen between the 
three groups.  The authors concluded that the effects of CRCI may be transient.   
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The first randomized study to compare two chemotherapy regimens of different 
intensity was conducted by van Dam et al. (1998).    In this study 34 women treated with 
high-dose chemotherapy plus tamoxifen were compared to 36 women who received 
standard-dose chemotherapy plus tamoxifen, and 34 controls who received local therapy only 
(mastectomy followed by radiation therapy or in conjunction with breast-conserving 
surgery).  High-dose participants received four standard cycles of fluorouracil, epirubicin, 
and cyclophosphamade (FEC) followed by high-dose cyclophosphamide, and thiotepa and 
autologous stem cell transplant.  Standard-dose participants received four or five cycles of 
FEC.  Eligible patients must have completed chemotherapy at least six months prior to the 
study.  Participants were evaluated with an array of 13 neurocognitive tests and measures for 
quality of life (QOL), anxiety, and depression.  Age and education level were taken into 
consideration.  Semi-structured interviews were conducted to evaluate participants’ self-
reports of cognitive changes.  The results indicated that 32% of the high-dose participants 
experienced cognitive impairment compared to 17% of the standard dose participants and 9% 
of controls.  No relationship was seen between objective cognitive measures and self-reports. 
As noted earlier, patients’ self-report of cognitive changes may be a more sensitive indicator 
of change than presently available neurocognitive tests (Schagan, et al. 2002).  No 
relationships were seen for time since last therapy, anxiety, or depression and cognitive 
function.  Participants in the high-dose group were at 8.2 times higher risk for cognitive 
impairment than controls (p = .006).  Participants in the standard-dose group were at 3.5 
times higher risk than controls (p = .056).   
 Since the work of van Dam et al., one additional study has been conducted to 
compare the impact of high-dose chemotherapy to standard dose regimens (Scherwath, et al., 
  
29
 
2006).    Scherwath et al. compared 24 high-dose participants with 23 standard-dose 
participants and 29 controls (women diagnosed with early disease that received surgery and 
radiation therapy).  High-dose participants received four cycles of epirubicin and 
cyclophosphamide (EC) followed by high dose cyclophosphamide, thiotepa, and 
mitoxantrone (CTM).  Standard-dose participants received EC followed by 
cyclophosphamide, methrotrexate and fluorouracil (CMF).  All hormone receptor positive 
participants received tamoxifen. The mean time since completion of chemotherapy was five 
years.  Comprehensive neurocognitive testing was conducted to assess the following 
domains: attention, memory, and executive function.  Participants who demonstrated 
impairment in four or more of the eighteen test parameters were classified as impaired in 
global neurocognitive performance.  Impairment was demonstrated in 8% of the high-dose 
group, 13% of the standard-dose group and 3% of controls.  The authors concluded that 
CRCI was substance dependent as opposed to dose dependent and credited methotrexate as 
the most neurotoxic agent of the two regimens.  No correlations were seen between 
tamoxifen use and changes in cognitive function.  Study results indicated that CRCI most 
frequently affected cognitive functions in the attention domain.  Least impairment was noted 
for executive function, a finding that was unexpected given the support for changes in 
executive function provided by other studies.  The authors acknowledged that this 
unexpected outcome may be due to the use of tests with insufficient sensitivity for measuring 
subtle cognitive impairments (see Table 3).   
Timothy Ahles and Andrew Saykin have contributed significantly to the state of the 
science about CRCI.  In 2002 they published results of a study to evaluate the 
neuropsychologic impact of standard dose systemic therapy in long-term survivors of breast 
  
30
 
cancer and lymphoma.  They compared the results of neurocognitive testing for patients with 
breast cancer (n = 35) and lymphoma (n = 36) who had received chemotherapy to patients 
who had received local therapy only, such as surgery or radiation therapy (n = 35, n = 22, 
respectively).  Survivors in both groups had to be at least 5 years post completion of their 
chemotherapy and without signs of CNS disease, history of CNS treatment, such as 
intrathecal treatment or radiation therapy to the brain, head injury, or neurologic disorder, or 
current administration of medications known to alter neuropsychologic functioning.  A 
standard array of neuropsychologic tests were selected to measure function in nine cognitive 
domains and all participants completed an 18-item self-report measure for perceived changes 
in memory functions.  Participants also completed instruments that measure anxiety, 
depression, and fatigue.  Demographic information was collected on age, gender, and 
education level as well as the type of therapy received, including hormonal therapy.  
Significantly lower scores were seen for participants receiving systemic versus local therapy 
(p < .04).  The domains of verbal memory (p < .01) and psychomotor functioning (p < .03) 
were most affected.  A neurocognitive performance index was calculated based on 
participants’ scores on all the neurocognitive tests.  Significantly more participants who 
received systemic therapy had low index scores (39% vs. 14%, p<.01) and reported greater 
problems with working memory (p < .02).  No significant differences were seen among the 
participants who had received hormonal therapy (tamoxifen) with those that had not.  No 
significant differences were seen between the participants with breast cancer versus those 
with lymphoma, lending support to the hypothesis that the phenomenon of CRCI may be 
similar for different types of malignancies. The authors noted that the chemotherapy 
regimens were very consistent for the two disease populations.  The authors concluded that 
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the study results demonstrated support for the hypothesis that systemic chemotherapy has a 
negative impact on cognition and that a subgroup of survivors may experience long-term 
cognitive deficits.   
Baseline Cognitive Impairment 
 Results of prospective trials are beginning to be published.  The first longitudinal trial 
to be conducted was designed to evaluate cognitive function at baseline, approximately three 
weeks following the completion of chemotherapy and any related medications known to have 
CNS activity (such as antiemetics) and 1 year post completion of chemotherapy (Wefel, et 
al., 2004).  The short-term post-chemotherapy time point was about 6 months after the 
baseline assessment.  The long-term time point was about 18 months after the baseline 
assessment.  Cognitive testing was selected to evaluate the domains of attention, processing 
speed, learning, memory, executive function, visuospatial function, and motor skill.  
Depression, anxiety, and self-report of quality of life also were measured.  The sample 
consisted of 18 participants who had received fluorouracil, doxorubicin, and 
cychophosphamide (FAC).  At baseline, 33% of the participants were classified as having 
cognitive impairment (impairment on 2 or more neurocognitive tests) and 24% exhibited 
impairment on verbal learning and memory compared to normative data adjusted for age, 
education, and gender (p = .02).  No mean group differences were seen between the short 
term and long term time points.  No statistically significant correlations were seen between 
cognitive performance and depression or anxiety at any time point.  Within subject analyses 
indicated that 61% of participants experienced a decline in cognitive function between 
baseline and the short-term time point.  No significant differences were seen for QOL.  For 
participants experiencing cognitive declines, 45% exhibited improvement at the long-term 
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time point and 45% demonstrated stable cognitive function.  The authors noted that despite 
the absence of a statistically significant mean group decline in cognitive function associated 
with FAC, a subset of women demonstrated a decline in function.  The most commonly 
affected domains were attention, learning, and processing speed.   
 The discovery by Wefel et al. that a third of women with breast cancer may 
experience cognitive changes prior to the initiation of chemotherapy was preceded by some 
research done by Cimprich and Ronis (2001).  Cimprich and Ronis (2001) defined one 
component of cognitive function as the capacity to direct attention (CDA), further described 
as the cognitive ability to actively block or inhibit a competing stimulus in purposeful or 
goal-directed activity (Cimprich, et al., 2005).  Aging has been associated with a loss of CDA 
in both men and women (Cimprich et al., 2005).  Cimprich et al. published results of a study 
in which women aged 55-79 who were newly diagnosed with breast cancer (n = 47) were 
evaluated for CDA and symptom distress before surgery, two weeks postoperatively, and 
three months postoperatively.  Healthy matched controls (n = 48) were evaluated at similar 
time frames.  The breast cancer group scored significantly lower than the healthy controls for 
CDA and symptom distress at baseline (p = .005) even though mean scores for CDA for both 
groups were within normal ranges for healthy adults.  Regression analysis was performed to 
assess the impact of age alone and group (breast cancer versus controls).  Age alone 
accounted for 6% of the variance at baseline with an additional 12% of the variance 
explained by group (p = .006).  Other variables (education, marital status, health problems, 
and depression) did not explain a significant proportion of the variance.   
 Cimprich et al. continued their work with a subsequent study designed to further 
evaluate the relationship of CDA with pertinent demographic and medical factors such as 
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age, menopausal status, education level, and comorbidities as potential predictors of CDA 
prior to treatment for breast cancer (Cimprich, et al., 2005).  Cognitive testing for two 
measures of CDA, memory, and self-report of cognitive function was performed for 184 
women with early stage disease (0, I, II) about 23 days after diagnosis by biopsy and about 
18 days prior to surgery.  Symptom distress and mood state also were measured.  Cognitive 
performance was within the normal range of healthy adults although participants’ self-report 
of cognitive function indicated that 50% reported moderate effectiveness and 25% reported 
lower effectiveness.  No significant relationships were seen between self-report and objective 
performance for attention or memory.  Age was significantly correlated with attention and 
memory as well as to self-report of cognitive function.  Younger participants had poorer 
effectiveness perception of cognitive function.  Significant differences were shown for 
memory (p < .05) and attention (p = .04) between pre and postmenopausal women.  No 
significant differences were seen for perimenopausal women.  More years of education were 
associated with better cognitive performance but no correlation was seen with self-report of 
cognitive function.  A relationship was seen between ratings of symptom distress and self-
reports of cognitive effectiveness.  Age and years of education were significant predictors of 
CDA prior to treatment.  Symptom distress and mood scores were significant predictors of 
self-report of cognitive effectiveness.  The authors suggested that younger women may 
perceive even small fatigue-related losses in attention that interfere with cognitive function 
but are not discernable with objective testing.  Older women were hypothesized to be at 
greater risk for treatment-related losses in CDA over time.  The authors stated that age may 
explain the observed relationship between menopausal status and cognitive functioning.  As 
in previous studies, the authors acknowledged that the objective cognitive tests may not be 
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sensitive enough to detect subtle changes in function or to replicate the complexity of the 
demands of daily life.   
Hormonal Influence on CRCI 
 Attribution of causality for CRCI in patients with breast cancer is complicated by the 
impact of estrogen inhibition on cognitive function.  The majority of breast cancer is 
diagnosed in postmenopausal women (approximately 75%) (Klemp, Stanton, Kimler, & 
Fabian, 2006) as the average age at diagnosis is 61 (NCI, 2009b).  Decreases in serum 
estradiol levels have been associated with changes in cognitive function.  Abrupt menopause 
is typically observed in premenopausal patients who receive chemotherapy.  Subsequent 
changes in cognitive function may be more pronounced in this population that does not have 
the more gradual onset of diminished estradiol levels normally experienced as women age.  
Studies designed to control for the use of hormonal therapy (selective estrogen receptor 
modulation with tamoxifen, or aromatase inhibition with anastrozole or letrozole) have 
produced conflicting results.   
 Paganini-Hill and Clark (2000) conducted a study with 1163 patients with breast 
cancer who took part in an earlier population-based case-control study.  Of these, 710 had 
taken tamoxifen and 453 had not.  Participants were stratified between past and current use as 
well as duration of therapy.  Standard-term tamoxifen users were defined as those who took 
tamoxifen for five years.  Participants completed three neurocognitive tests that were 
supplied and returned by mail.  Little difference was seen between standard-term tamoxifen 
users and never users.  However, standard-term users reported seeking attention from their 
physicians for memory problems (3.8% vs 1.5%, p = .04) and those currently receiving 
tamoxifen demonstrated a lower score on the narrative writing task (p = .03).  The authors 
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concluded that current use of tamoxifen may adversely affect cognition.  This study was 
limited by the lack of personal administration of the three neurocognitive tests as no direct 
observation of tests performance was possible nor was the opportunity to verify participants 
understood the instructions.  
 The effects of hormone therapy on cognition in breast cancer recently was studied as 
a component of the anastrozole, tamoxifen and combined (ATAC) trial (Jenkins, Bloomfield, 
Shilling, & Edginton, 2005; Shilling, Jenkins, Fallowfield, & Howell, 2003).  Women on this 
trial with no evidence of disease (n = 94) were compared to a convenience sample of healthy 
post-menopausal women (n =35).  No patients on this trial received chemotherapy.  
Neurocognitive tests were conducted to assess auditory-verbal memory, visual memory, 
working memory and attention, processing speed, vigilance, and intelligence.  Participants 
also completed instruments to measure anxiety and depression as well as a 25-item self-
report instrument to describe cognitive impairment.  Participants receiving hormonal therapy 
had significantly lower scores for immediate verbal recall (F = 4.57, p = .034) and processing 
speed (F = 3.96, p = .049). No differences were seen between the groups for the remaining 
domains.  The authors concluded that hormone therapy did not affect overall cognitive 
performance, but did impair performance on tests of verbal memory and processing speed.   
 Another study conducted to evaluate the impact of chemotherapy on cognitive 
function also explored the impact of hormonal therapy (Castellon, et al., 2004).  Participants 
were part of a larger study (the Cancer and Menopause Study- CAMS), who were between 
two and five years from diagnosis, age 50 years or younger, with no evidence of disease 
recurrence.  Participants were excluded for history of neurologic or psychiatric disorder, 
current or past history of drug or alcohol use disorder, or use of any medications that might 
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impact neurocognitive performance.  Participants were diagnosed with early stage disease (I, 
and II) and were compared to healthy, age-matched women recruited specifically for this 
study.  Measures included instruments to assess function across eight cognitive domains, in 
addition to depression, anxiety, and fatigue.  The sample consisted of breast cancer survivors 
(n = 53) and healthy comparison controls (n = 19).  Of the breast cancer survivors, 17 
received only local therapy, 18 received chemotherapy alone and 18 received chemotherapy 
with the addition of tamoxifen.  Most of the women received cyclophosphamide, 
methotrexate and fluorouracil (CMF, 41%) while 38% received a doxorubicin containing 
regimen with either cyclophosphamide alone or with CMF.  The remainder received 
doxorubicin, cyclophosphamide, and a taxane (ACT, 9%).  Significant differences in 
performance for verbal learning (p = .03) visuospatial functioning (p = .005), and visual 
memory (p = .01) were seen for the women receiving systemic therapy versus local therapy.  
Global neurocognitive performance scores also were significantly lower for the systemic 
treatment group (p = .01).  Women who received both chemotherapy and tamoxifen had the 
lowest group means on five of the eight cognitive domains and significantly lower global 
neurocognitive performance scores than the women who received chemotherapy alone (p = 
.02).  As with many studies, lack of correlation was seen between self-report of cognitive 
function and the objective measures potentially due to the lack of sensitivity of available 
neurocognitive tests (Jacobs, et al. 2007).  Significant correlation was observed between poor 
cognitive performance with depression (r = .44, p < .01), anxiety (r = .42. p < .05), and 
fatigue (r = 1.39, p < .05).  The authors acknowledged that study limitations included small 
sample size and cross-sectional design. The authors concluded that the study provided 
  
37
 
support for CRCI in a subset of breast cancer survivors and that adjuvant tamoxifen may 
have subtle but lasting cognitive effects in breast cancer survivors. 
 A more recent study was conducted to compare memory impairment seen with 
adjuvant anastrozole versus tamoxifen for women with early-stage breast cancer (Bender, et 
al., 2007).  Due to evidence to support lower serum estradiol levels with aromatase inhibition 
compared to selective estrogen receptor modulation, Bender et al. hypothesized that 
anastrozole would have a more profound effect on cognitive function than tamoxifen.  A 
cross sectional design was used to evaluate cognitive function, depression, anxiety, and 
fatigue for 31 postmenopausal women who had received tamoxifen (n = 15) or anastrozole (n 
= 16) for a minimum of 3 months.  Cognitive testing was conducted for the domains of 
attention, learning and memory, psychomotor efficiency, mental flexibility, visuospatial 
ability, and general intelligence.  The variables of age, years of education, time on hormonal 
therapy, depression, anxiety, and fatigue were controlled.  Women receiving anastrozole had 
significantly lower scores on measures of learning and memory.  However no significant 
difference was noted for any of the other cognitive domains.  Hierarchical regression was 
calculated for the controlled variables (block 1) and the addition of anastrozole and 
chemotherapy for each cognitive test of learning and memory.  Anastrozole contributed a 
unique explanation of variance for the models of verbal learning and memory (12-35%) as 
compared to the variance explained by chemotherapy (.1-6%).  Study limitations included 
small sample size, cross-sectional design, and lack of baseline measures prior to initiation of 
chemotherapy and hormonal therapy. 
 Klemp et al. (2006) evaluated the effects of chemotherapy on cognitive function and 
QOL for premenopausal women with breast cancer. The sample consisted of 20 women with 
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breast cancer receiving chemotherapy with doxorubicin and cyclophosphamide, epirubicin 
and cyclophosphamide, trastuzumab or carboplatin and docetaxel.  Cognitive function, 
depression, fatigue, QOL, serum estradiol levels and hemoglobin levels were measured at 
baseline, half-way through chemotherapy, and approximately three weeks following the 
completion of chemotherapy (prior to the initiation of any hormonal therapy or radiation).  
Cognitive domains included: memory, language, attention and concentration, visuomotor, 
spatial, and executive function.  Patients receiving either adjuvant or neoadjuvant (50%) 
chemotherapy were eligible.  Estradiol levels significantly decreased from baseline (p = 
.009).  Participants reported menopausal symptoms that caused depression (p = .001) and 
affected QOL.  Participants perceived impairment of concentration and memory although 
impairment was not demonstrated on the objective neurocognitive tests.  Cognitive function 
scores actually improved over time which the authors attributed to practice effect. 
Additional work related to the impact of menopausal symptoms and fatigue to 
cognitive function was conducted by Tchen, et al. (2003).  A sample of 110 women receiving 
adjuvant chemotherapy nominated an age-matched volunteer to total 100 matched pairs for 
evaluation.  Eligible participants were age 60 or younger and had completed at least three 
courses of chemotherapy at the time of assessment.  Preferred time for assessment was within 
two to six weeks of the previous chemotherapy treatment.  Premenopausal status was defined 
as menses within the past 3 months, perimenopausal as menses within 3-12 months, and 
postmenopausal as no menses for >12 months.  Participants were tested for cognitive 
performance in the following domains: verbal memory, language, visuomotor, spatial, 
attention and concentration, and executive function.  Reaction time and psychomotor speed 
also were assessed in addition to self-report of fatigue, menopausal symptoms and QOL.  The 
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majority of participants were receiving combinations of cyclophosphamide, epirubicin, 
fluorouracil, doxorubicin, and methotrexate.  Five participants were receiving tamoxifen.  
Hemoglobin levels were collected and included in multivariate analysis for possible effects 
on cognitive function and fatigue.  Participants receiving chemotherapy demonstrated poor 
cognitive function compared to controls (p = .0008). Co-variates of age, education, and 
menopausal status did not alter the statistically significant difference between the group 
receiving chemotherapy and the controls (p = .008).  Fatigue was more significant in the 
chemotherapy group (p < .0001).  Sixty-two percent of participants were menstruating prior 
to starting chemotherapy, but only 25% were menstruating at the time of the assessment.  
Participants receiving chemotherapy had significantly more severe menopausal symptoms (p 
< .0001) and lower QOL scores (p < .0001).  Objective tests of cognitive function were not 
correlated with fatigue, menopausal symptoms or QOL, however strong relationships were 
seen between fatigue and QOL (p < .0001), menopausal symptoms and QOL (p < .0001), and 
fatigue and menopausal symptoms (p < .0001).  The authors noted that only 16 participants 
had moderate or severe cognitive dysfunction (less than expected), so the study was 
insufficiently powered to make definite conclusions about the influence of fatigue, 
menopausal symptoms, type and number of courses of chemotherapy, hemoglobin level on 
the probability of cognitive dysfunction.  Scores for objective tests of cognitive function were 
not correlated with scores for QOL.  The authors stated that they believed methotrexate to be 
the most neurotoxic of the chemotherapeutic agents.  Since only 11 patients in this study 
were receiving a methotrexate containing regimen the relationship between specific drugs 
and cognitive effects could not be evaluated.  They noted feeling reassured that the 
fluorouracil, epirubicin, cyclophosphamide, (FEC) regimen was more intensive but did not 
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lead to an increase in cognitive dysfunction.  The authors stated that the study results did not 
support a hormonally mediated mechanism for causing cognitive dysfunction.   
 Follow-up to the work was published in 2005 (Mar Fan, et al., 2005).  Participants 
were re-evaluated at 1 and 2 years of follow-up.  The proportion of patients with moderate-
severe cognitive impairment decreased from 16% to 4% after 2 years.  No significant 
difference was seen between patients who received hormonal therapy and those that did not.  
Similar levels of QOL were reported by both participants who received chemotherapy and 
controls at 1 and 2 years of follow-up.  The authors did acknowledge that practice effect 
might have masked a small effect of tamoxifen on cognitive function.  Over the 2 year 
follow-up period, a very small number of participants received an aromatase inhibitor.  No 
conclusions were drawn related to aromatase inhibition versus selective estrogen receptor 
moderation with tamoxifen.   
Prospective longitudinal studies provide the benefit of being able to compare baseline 
data about cognitive function to changes that may occur during or after completion of 
chemotherapy.  One such study published in 2006 (Bender, et al., 2006) was designed to 
compare changes in cognitive function across three groups of breast cancer survivors (n = 
46).  Bender et al. evaluated women with stage I or II breast cancer with hormone receptor 
negative disease who received chemotherapy alone (n = 19), to women with hormone 
receptor positive disease who received chemotherapy in addition to hormonal therapy with 
tamoxifen (n = 15).  The control group was comprised of women with ductal carcinoma in 
situ who received neither chemotherapy nor tamoxifen (n = 12).  Cognitive function was 
measured after surgery in the non-treatment group and just prior to initiation of adjuvant 
therapy in both treatment groups (Time 1).  Additional measurements were conducted within 
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1 week after completion of chemotherapy (Time 2) and at a comparable time for the non-
treatment group.  Time 3 measurement was conducted 1 year after Time 2.  The 
neurocognitive test array was selected to measure the domains of attention, learning and 
memory, psychomotor speed, mental flexibility, visuoconstructional ability, executive 
function, and general intelligence.  Participants’ also completed a self-report measure for 
perceptions of cognitive function.  Potential moderators of cognitive function also were 
assessed, including: depression, anxiety, fatigue, and concomitant medications.  The 
chemotherapy regimens all included cyclophosphamide, however the regimens were not 
consistent related to the other antineoplastic agents (methotrexate, fluorouracil, doxorubicin, 
and a taxane).  Attrition occurred for all three groups (10 at Time 2 and 14 at Time 3) due to 
drop-outs for “being too busy” (80%) or progression of disease (20%).  The attrition rate was 
not different across the groups and no significant differences were seen between women who 
dropped out and women who remained on study.  Women scoring higher on the depression 
measure were noted to perceive more cognitive problems. No interaction was seen for 
anxiety or fatigue with cognitive function.  No significant differences in cognitive function 
were seen at baseline.  The performance of the treatment groups for memory measures 
deteriorated over time.  Overall, women receiving chemotherapy alone or with tamoxifen had 
significantly worse performance on memory tests over time than the women in the non-
treatment group (p = .026) at Time 3.  Women who received only chemotherapy performed 
better than women who also received tamoxifen (p = .043) at Time 3. Women who received 
both chemotherapy and tamoxifen demonstrated deterioration in tests of immediate recall 
between Time 2 and Time 3 (p = .017).  The broadest deteriorations were seen for visual 
memory and verbal working memory by the women who received both chemotherapy and 
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tamoxifen.  The authors concluded that CRCI was domain specific as opposed to diffuse.  
The authors attributed the difference to the pre-treatment baseline evaluation that is a 
component of prospective trials.  Very little objective variation from baseline was seen at 
Time 2, although participants’ self-report of changes in cognitive function were immediately 
evident at the conclusion of therapy.  As with many other studies, there was no correlation 
between objective and subjective measures of cognitive function.  The authors recommended 
shorter measurement intervals in future studies to try and more precisely capture when 
objective changes in cognitive function occur.  Strengths of this study included baseline 
evaluation of cognitive function and evaluation of cognitive function at uniform times after 
completion of chemotherapy.  Limitations included the small sample size, attrition rate, and 
lack of consistency for chemotherapy regimens.  The authors noted that their study results 
reinforce the subtlety of cognitive changes related to chemotherapy and that the deficits may 
be limited to memory.  They also stated that CRCI may be manifested with recall of recently 
learned information, particularly in situations where distractions occur and women with 
CRCI have difficulty working effectively in cognitively challenging situations.   
A prospective trial by Jenkins et al. (2006) was conducted to study the effects of 
adjuvant chemotherapy and hormonal therapy on cognition in women with early stage breast 
cancer. Cognitive testing was performed for 85 women scheduled for chemotherapy, 43 
scheduled for hormonal and/or radiation therapy, and 49 healthy controls at baseline (T1), 
post chemotherapy or 6 months (T2), and at 18 months (T3).  Hormonal therapy regimens 
included tamoxifen, goserelin, and aromatase inhibitors.  No group differences were 
observed, but individual declines were seen in 20% of chemotherapy patients, 26% of 
hormonal therapy patients, and 18% of controls at T2 and T3 (18%, 14%, 11%).  Participants 
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who experienced a treatment-induced menopause showed more decline at T2 (p = .086).  
Self-reports of cognitive function were associated with QOL scores (p < .0001), but no 
correlation was seen with objective cognitive tests.  A majority of participants receiving 
chemotherapy noted changes in memory (83%) and concentration (80%) at T2.  
Improvements were seen at T3 (60%, and 45%).  Reliable predictors of cognitive 
performance were determined to be age, intelligence, and years of education.  No association 
was seen for objective cognitive performance with chemotherapy, hormonal therapy, QOL 
and psychological distress.  The authors noted that most of the participants in the 
chemotherapy group received low dose fluorouracil, epirubicin, and cyclophosphamide 
(FEC).  The authors concluded that the study results suggested only a small proportion of 
women receiving adjuvant therapy for breast cancer experience objective declines in 
cognitive function and those experiencing treatment-induced menopause, particularly in the 
initial period following chemotherapy, appear to be at greatest risk. 
Self-Report of CRCI 
 Participants who took part in the  studies by Tchen et al. and Mar Fan et al. (described 
above) also had the opportunity to participate in semi-structured interviews performed to 
gather descriptive information about the symptoms and subsequent meaning and impact on 
participants’ day-to-day lives (Downie, Mar Fan, Houede-Tchen, Yi, & Tannock, 2006).  
Every second patient recruited during a defined time interval of the larger study was invited 
to participate in the interviews and complete an assessment of cognitive function as well as a 
self-report questionnaire (Functional Assessment of Cancer Therapy- General, Fatigue and 
Endocrine Symptoms Subscales).  The sample included 21 participants without evidence of 
recurrence or metastases and no history of major physical or psychiatric illness.  Patients 
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were excluded for psychotropic medications with the exception of benzodiazepines or 
serotonin reuptake inhibitors.  Participants were asked about whether they had noticed 
changes in memory, concentration and attention, verbal ability, thinking speed, spatial 
ability/orientation, and the ability to plan and organize (executive function) as well as fatigue 
or menopausal symptoms.  If participants answered yes to any of these areas, they were then 
asked to describe the symptom, how the symptom had changed from prior to the start of 
chemotherapy, how the symptom changed their life, how they coped with the symptom, and 
the level of severity with which they would rate the symptom (mild, moderate, or severe).  In 
this mixed-methods design, the severity descriptors were assigned a numerical value 
(normal/borderline = 0, mild = 1, moderate = 2, severe = 3).  Correlations were examined 
between the interview responses and participants’ scores on the quantitative measures of 
cognitive function, fatigue, and menopause.  Fatigue was reported by 90% of patients on the 
quantitative instrument and 100% in the interviews.  Menopausal symptoms were reported on 
94% of the quantitative instrument and 83% during the interview.  Objective measures of 
difficulty with language (61%) and memory (48%) contrasted with those reported during the 
interview (78% and 95%).  The biggest disparity occurred between objective measures of 
attention and concentration (10%) and those reported in the interview (90%).  Significant 
correlations were seen between objective cognitive performance for fatigue (p = .001), 
menopausal symptoms (p = .05), and memory (p = .008).  Participants said that fatigue, 
nausea, and cognitive problems interfered with the ability to maintain full-time employment.  
About 30% of participants were able to work part-time.  Participants complained of changes 
in short-term memory, concentration, verbal fluency and word finding, processing speed, and 
executive function.  These problems were described to be intermittent and unpredictable.  No 
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participants complained of difficulty with verbal comprehension.  Participants noted a great 
change in their ability to multi-task.  Few participants noted difficulty with spatial ability, 
however about 10% complained of decreased sense of direction and distance judgment.  
Several noted changes in their ability to drive due to trouble with concentration, memory, and 
processing speed.  The authors acknowledged that the sample size was large for qualitative 
investigation, but small for statistical analysis.  The authors concluded that quantitative self-
report measures and semi-structured interviews are important to gain a comprehensive and 
clinically relevant understanding of the symptom experience.   
The importance of self report for CRCI has been emphasized in the literature. Lynne 
Wagner and colleagues continue to develop the Functional Assessment of Cancer Therapy-
Cognition instrument (Wagner, Sweet, Butt, Lai, & Cella, 2009).  The results of qualitative 
interviews and focus groups were used to generate the self-report measure of chemotherapy-
related cognitive function. Due to the profound impact of perceived cognitive impairment on 
functional abilities and quality of life, Wagner et al. advocate the position that patient-
reported cognitive function is an important study endpoint.  
Further support for the importance of self-report of CRCI was generated by the work 
of Andrew Saykin in which an association was seen between patient self-report of cognitive 
changes and neuroimaging (Saykin et al. 2006). In this work neuroimaging was used to 
compare decline in gray matter volume between older adults with self-report of memory 
complaints and normal performance on memory tests with individuals demonstrating mild 
cognitive impairment on testing as well as healthy controls. Results of the study indicated 
that self-report of memory complaints was associated with gray matter loss prior to decreased 
performance on objective memory tests.  
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Contradictory Findings  
 Many aspects of the research conducted to date are contradictory, as evidenced by 
two recent meta-analyses conducted to examine the neurocognitive effects of cancer therapy 
and address the issue of the magnitude of cognitive impairment due to chemotherapy 
(Anderson-Hanley, Sherman, Riggs, Agocha, & Compas, 2003; Falleti, Sanfilippo, Maruff, 
Weih, & Phillips, 2005).  Anderson-Hanley et al. evaluated 30 studies involving various 
cancer therapies such as chemotherapy, radiation therapy, immunomodulatory therapy, and 
bone marrow transplant for a variety of malignancies (n = 838).  They noted consistent 
statistically significant negative effect sizes across both normative and control methods for 
executive function, verbal memory, and motor function.  Anderson-Hanley et al concluded 
that no clear clinical implications could yet be drawn as more research is needed to clarify 
which treatments are associated with cognitive impairment and to further rule out the wide 
variety of possible mediating or moderating variables such as: total brain irradiation, central 
nervous system disease, and immunologic therapy, treatment intensity, severity of diagnosis, 
stress, fatigue, depression, inflammatory cytokines, and concomitant medications.  Anderson-
Hanley stated that the effect sizes across all the studies for executive function, verbal 
memory, and motor function indicated that cognitive performance for patients receiving 
systemic therapy was one third to almost one standard deviation below normative samples or 
control groups.  This performance level is not as low as what would traditionally warrant a 
label of impairment by neurocognitive standards (-1 to -3 standard deviations).  As such, the 
deficits may be difficult to observe.  Anderson-Hanley et al. discussed the impact that subtle 
changes in cognitive function would have on individuals with average or above-average 
baseline function and the distress associated with the inability to continue performing in a 
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profession that requires peak cognitive skills.  Anderson-Hanley et al. also noted that further 
research for CRCI may clarify the potential need for more detailed informed consent prior to 
initiation of chemotherapy.  More knowledge about CRCI would serve to validate some 
patients’ experiences while enhancing the pre-treatment anxiety of others.  Specific 
knowledge regarding who is at greatest risk for CRCI may relieve those who are likely to 
experience smaller or more reversible declines in cognitive function. 
 Falleti et al. conducted a meta-analysis specific to CRCI in women with breast 
cancer.  Only six studies met their inclusion criteria (n = 208) (five cross-sectional and one 
prospective).  Their results were somewhat contradictory to much of the literature to date.  
Regression analysis indicated a significant negative logarithmic relationship (R2 = .63) 
between effect sizes and time since last receiving chemotherapy, percentage of patients 
currently taking tamoxifen (R2 = .60), and average age (R2 = .67).  No relationship was seen 
between the percentage of patients on tamoxifen and cognitive function.  The prospective 
effect sizes indicated improvements in cognitive function from the beginning of 
chemotherapy to one year following treatment. Falleti et al. compared CRCI with the fatigue 
that occurs at the end of a normal day (twelve hours of wake time).  Falleti et al. criticized 
studies that used multiple neurocognitive tests for each cognitive domain, stating that the 
more tests used to assess cognitive performance, the greater the probability that an individual 
would meet the criteria for impairment.   
Descriptions of CRCI and the Breast Cancer Experience 
 Very few qualitative studies have been published that specifically relate to the 
experience of CRCI for women with breast cancer.  Support in the literature exists for the 
need of information related to long-term sequelae from the treatment of breast cancer 
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(Cappiello, Cunningham, Knobf, & Erdos, 2007).  Cappiello et al. recently conducted a 
qualitative study to “describe the information and support needs of women with early-stage 
breast cancer after treatment, as a basis for developing specific interventions” (p. 280).  A 
series of 16 semi-structured interviews were conducted (8 in-person, and 12 by phone) for 
women with early stage breast cancer (0-IIIA) diagnosed within the past 5 years who had 
completed primary and/or adjuvant treatment (with the exception of hormonal therapy).  
Participants were questioned about physical symptoms at 3, 6, and 12 months following 
treatment.  Fatigue was the most prevalent symptom reported.  However difficulty 
concentrating was reported by 60% at three months.  Difficulty remembering things was 
reported by 80% at three months.  These symptoms persisted (55-75% respectively) 
throughout the first year following treatment.  Participants also were asked to describe their 
emotions following treatment.  Anxiety was common during the 1st year (ranged from 50-
60%).  Changes in mood (50%) and feeling sad (20%) diminished over time (20% and 5%).  
Participants described struggling to return to the life they led before their breast cancer 
diagnosis.  The authors concluded that a need exists to provide comprehensive information 
and support to prepare women for the transition from cancer treatment to long-term 
survivorship.  The authors acknowledged that the study was limited by the small, cross-
sectional sample, homogenous demographics (90% Caucasian), and dependence on 
participants’ recall of symptoms the year following treatment. 
Two recent works were completed to better understand the experience of CRCI for 
patients with breast cancer (Mulrooney, 2007; Thielen, 2009).  Mulrooney conducted a 
phenomenological study to examine the experience of CRCI on day-to-day life.  She 
interviewed 10 women who were within 15-52 months of completing their chemotherapy that 
  
49
 
self-reported cognitive impairment.  Participants were recruited from two larger studies being 
conducted at Dartmouth that included longitudinal standard neurological testing prior to and 
after chemotherapy (n = 9) and functional magnetic resonance imaging (fMRI) (n = 1).  Each 
participant was interviewed twice.  The second interview (4-8 weeks following the first) 
provided an opportunity for member checking as well as the collection of additional 
information after participants had some time to reflect on their experiences.  Mulrooney also 
collected e-mails received from participants, field notes, and an electronic journal of her 
thoughts throughout the study.  Participants were asked to describe how CRCI had interfered 
with their ability to function in any aspect of their day-to-day lives and what, if any, 
strategies they had devised for handling the problem.  Mulrooney described a bracketing 
exercise to attempt to separate knowledge and prejudices about the phenomenon.  Her data 
analysis procedure was well described.  Mulrooney noted three themes from her analysis: 1) I 
just don’t feel like me; 2) Trying my best to live with it; and 3) I am alive.  The analysis 
process produced a final theme that participants believed CRCI was a result of necessary 
treatment to save their lives, and thus focused most on survival.  Mulrooney summarized 
participants’ difficulties with memory, learning, concentration, language, and multitasking 
ability.  Concrete coping skills were described as: keeping a calendar, writing lists, putting 
frequently used items in the same place to prevent loss or dependence on family for 
assistance.   
Thielen also conducted a phenomenological study of the experience of neurocognitive 
changes in women undergoing chemotherapy for breast cancer.  The purpose of her study 
was to describe and enrich the understanding of what CRCI means to the individual and the 
effect it has on everyday life.  Thielen hoped the insights obtained from the study would be 
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useful in the design of screening questionnaires, educational products, and interventional 
strategies.  Thielen listed her research question as, “What is the lived experience of 
neurocognitive changes in women undergoing adjuvant chemotherapy for breast cancer?”  
Thielen outlined her presuppositions about breast cancer, side effects and the impact on 
women.  Participants were recruited through an advertisement in the local newspaper and 
contacts in the offices of private oncology practices.  Efforts were made to include women 
from diverse ethnic and racial groups.  Eligible participants were women who self-reported 
changes in memory, attention, and/or concentration since undergoing chemotherapy.  
Participants could be currently receiving treatment or within 3 months of completion.  
Unstructured interviews were conducted with 13 women.  Colaizzi’s method for 
phenomenological data analysis was used.  Thielen identified the following eight themes: 1) 
Insidious recognition and delayed validation of cognitive changes; 2) Looking for answers in 
all the wrong places; 3) Attention: Can’t keep my eye on the ball; 4) Underwhelming 
information for an overwhelming experience; 5) Work department: Hold please!; 6) Missing 
label: Caution- women on chemotherapy on board; 7) Coping: not on the journey alone; 8) 
What the future holds.    
Participants complained that they didn’t know what was happening to them which 
added to the distress associated with the cognitive changes they were experiencing.  This 
complaint lends support to the need for HCPs to provide appropriate pre-treatment education 
and to validate patients’ experiences as they are identified or reported.  Three of Thielen’s 
themes included the need for information and validation: 1) Insidious recognition and 
delayed validation of cognitive changes; 2) Looking for answers in all the wrong places; and 
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4) Underwhelming information for an overwhelming experience.  Further analysis may have 
led to the combining of these three themes into one.  
Participants described difficulty with concentration, distraction, and indecisiveness.  
Complaints included deficits in being able to remember names and telephone numbers and 
do simple math (short and long term memory and executive function).  They associated these 
changes with decreased QOL.  One participant was unable to return to work.  Many 
participants did not have to work full time but expressed doubt over whether they would be 
able to do so due to the changes in cognitive function they experienced.  Participants 
described difficulty driving due to impaired sense of direction and inability to remember how 
to get to familiar places.  Family members were needed to assist with accurate administration 
of home medication due to inability to remember whether a dose had been taken or not.  
Most participants were hopeful that they could return to a pre-treatment cognitive state.  
Thielen stressed the need for appropriate assessment and education of patients 
receiving chemotherapy for breast cancer.  She recommended replicating this study with a 
more diverse sample demographically and geographically in addition to triangulation from 
patients’ medical records regarding types of chemotherapy regimens. 
Boykoff et al. recently published results of an exploratory pilot study to investigate 
post-treatment side effects of breast cancer survivors.  Participants were at least one year 
post-completion of adjuvant radiation and/or chemotherapy.  Both focus groups and in-depth 
interviews were conducted with 74 women (20 women participated in both) to explore the 
effects that cognitive impairment has on women’s personal and professional lives.  Eligible 
women self-reported changes in cognitive function.  The investigators used terminology such 
as loss of words, forgetfulness, memory loss, or chemobrain when querying participants 
  
52
 
about CRCI.  Data were analyzed using ethnographic content analysis and codes that were 
developed a priori to the study.  Participants reported 15 discrete, chronic symptoms 
attributed to cancer therapy.  Cognitive impairment was reported by 70% of the sample.  
Participants described difficulty remembering numbers, trouble with word-finding, decreased 
processing speed, and diminished ability to read complex books.  Lack of acknowledgement 
of CRCI by the medical community was a common complaint.  Participants noted they 
wished they had received some warning about the potential for CRCI.  A number of 
participants described lack of understanding from family and friends and many shared issues 
and concerns with maintaining their previous level of wage earning and work-related 
performance.  Some coping strategies included the use of calendars and post-it notes as well 
as some social withdrawal due to difficulty in following conversation.  The investigators 
acknowledged the importance of in-depth interviews as compared to questionnaires to truly 
learn about survivors’ experiences and recommended further qualitative work to gain 
knowledge of the interplay between CRCI and resultant life experience. 
Summary and Support for Current Research 
 The review of literature related to the experience of CRCI for women with breast 
cancer yielded a number of gaps and contradictions in the state of the knowledge.  
Controversy exists over whether potential predictive factors are related to CRCI or not.  
Results of several studies did not show significant correlation or impact on cognitive function 
for a variety of factors including: age, education level, menopausal status, time since 
treatment, treatment regimen, anxiety, depression, and fatigue (Brezden et al., 2000; Schagen 
et al., 1999, 2002; van Dam et al., 1998; Wieneke & Dienst, 1995). However, these results 
were contradicted by Castellon et al. (2004) who found a correlation between cognitive 
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impairment and depression, anxiety, and fatigue.  Likewise, Jenkins et al. (2006) found age, 
intelligence quotient, and education level to be predictors of cognitive performance.  Anxiety 
and depression have been shown to be related to a negative impact on quality of life and may 
contribute to enhanced perception of cognitive changes (Klemp et al. 2006).   
 Jenkins et al. (2005) found hormonal therapy to be associated with declines in verbal 
memory and processing speed and Bender et al. (2006) noted that combination chemotherapy 
and hormonal therapy was associated with higher levels of cognitive changes than 
chemotherapy alone or no therapy.  Mar Fan et al. (2005) found no significant differences in 
cognitive function for women who received hormonal therapy.   
 The semi-structured interviews conducted by Downie et al. (2006) yielded 
information about the intermittence and unpredictability of cognitive changes women with 
breast cancer experienced.  Mention was made of difficulty maintaining employment, 
multitasking, and sense of direction.  This study provided support for both quantitative self-
report measures and semi-structured interviews to better understand the symptom experience 
of CRCI.  Bender et al. (2006) noted that patients’ self-report of cognitive change was 
present immediately at the conclusion of chemotherapy as compared to a more delayed 
evidence on objective measures.  This information matches the experience described by 
Saykin et al. (2006) whereby self-report precedes changes seen by neuroimaging. 
 Results of the qualitative work by Boykoff et al. (2009), Cappiello et al. (2007), 
Mulrooney ( 2007), and Thielen (2008) indicated that women with breast cancer would 
benefit from receiving comprehensive information and support related to the potential for 
cognitive changes from chemotherapy.  Boykoff’s results demonstrated a lack of 
acknowledgement of CRCI by the medical community as well as the importance of in-depth 
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interviews with cancer survivors. Thielen’s descriptions of women who “didn’t know what 
was happening to them” and the “need for information and validation” are strong indicators 
for the development of meaningful educational materials.  Thielen described one woman who 
was unable to return to work as a result of cognitive changes.  Very little information is 
available in the literature related to the impact of CRCI on the ability to maintain 
professional and personal roles. 
Evidence of the lack of agreement and standardization of objective measures of 
cognitive performance for women with breast cancer who have received chemotherapy is 
clear.  Lack of congruence between self-reports of cognitive changes and performance on 
neurocognitive tests has been demonstrated repeatedly.  Self-report measures are credited 
with higher sensitivity than standard neurocognitive tests to the subtle changes in cognitive 
function experienced by women with high levels of baseline function.   
Further qualitative exploration of the patient experience has the potential to 
significantly add to the state of the knowledge about CRCI.  Obtaining rich, detailed 
descriptions from women with breast cancer about the experience of CRCI may validate 
earlier qualitative work.  Ascertaining specific information that women with breast cancer 
would have found helpful prior to starting treatment with chemotherapy is necessary to 
provide a framework to develop meaningful educational tools.  A better understanding of the 
experience of CRCI is needed to educate HCPs and lead to an improved process of informed 
consent as well as validation of the patient experience.  The following qualitative descriptive 
research study was designed to add to the body of knowledge related to the experience of 
CRCI for women with breast cancer and desired timing and content of related education. 
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Chapter 3: Methods 
 The study was designed to address the following problem: Women with breast cancer 
complain of a lack of acknowledgement and education about the potential for cognitive 
changes related to chemotherapy.  Cognitive changes can have a significant impact on cancer 
survivors’ quality of life and lack of information regarding the potential risk for 
chemotherapy-related cognitive impairment (CRCI) prevents obtaining full informed consent 
prior to initiation of therapy. Lack of acknowledgement of CRCI by HCPs is a source of 
frustration and dissatisfaction to patients experiencing cognitive changes. The purpose of this 
qualitative descriptive study was to provide an in-depth description of the patient experience 
of CRCI for women with breast cancer.  
Study Design 
 A qualitative descriptive design was selected to answer the research questions 
because this methodology is particularly suited to obtaining straightforward answers of 
interest to practitioners (Sandelowski, 2000) .  Data were collected through the use of semi-
structured interviews and a focus group. Triangulation of data between the interviews and 
focus group occurred as the data were analyzed and interpreted. This approach was used to 
enhance study credibility. 
Setting 
 Participants were recruited from the University of Kansas Medical Center (KUMC) 
Breast Cancer Survivorship Center (BCSC).  Participants also were recruited by referral from 
members of the Greater Kansas City Chapter of the Oncology Nursing Society. Self-referrals 
also were accepted by eligible interested women who became aware of the study through 
conversations with friends/family participating in the study. 
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 The KUMC BCSC was selected for the study due to the large potential pool of 
eligible women (about 800) and interest on the part of the staff in the area of CRCI.  The 
Managing Director of the BCSC was a member of the research team and has conducted 
research related to CRCI in women with breast cancer.   
Sample 
 Purposive sampling (a qualitative sampling technique that involves deliberate, non-
random recruitment of participants to meet pre-established eligibility criteria) was used for 
recruitment to the study.  Eligible participants included adult women (18 or older) diagnosed 
with any stage of breast cancer, who were within 6-12 months of completing chemotherapy 
and self-reported changes in cognitive function.  Self-report included voluntary, unsolicited 
description of changes in cognitive function to the potential participant’s HCP (oncologist or 
oncology nurse) or the Managing Director of the KUMC BCSC. Examples of changes in 
cognitive function included (but were not limited to) complaints of mental fogginess, 
difficulty concentrating, trouble with memory, inability to multitask or do mathematic 
calculations, and decreased sense of direction when driving.   
The following additional inclusion criteria applied: ability to read, write, speak, and 
understand English in order to read and understand the informed consent and demographics 
questionnaire.  Any questions related to the informed consent or questionnaire were 
explained in person by the investigator. Women were excluded from the study if they had 
evidence of severe cognitive impairment (exhibited lack of understanding and/or inability to 
repeat the purpose of the study during the process of informed consent with the investigator), 
central nervous system metastases, a history of mental illness, dementia, or Alzheimer’s 
disease or were currently taking psychotropic medications (with the exception of 
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benzodiazepines or selective serotonin reuptake inhibitors prescribed for the treatment of 
anxiety or depression).  Any standard-dose regimen of chemotherapy was accepted as was 
current or past hormonal therapy (selective estrogen receptor modulation or aromatase 
inhibition).  Medical and medication history were confirmed by the referring HCP as initial 
eligibility was assessed prior to providing the investigator’s contact information to interested 
women.  Eligibility was confirmed by the investigator during the in-person meeting to obtain 
informed consent. 
A sample size of approximately 15 participants for the semi-structured in-depth 
interviews was predicted to achieve data saturation.  The sample size prediction was based on 
previous qualitative work conducted by Thielen (n = 13), Mulrooney (n = 10) and Capiello  
(n = 16).  Sampling continued until no new information was obtained during the in-depth 
semi-structured interviews. 
Procedures 
 Safety. Approval was granted by the KUMC Protocol Review Monitoring Committee 
and Human Subjects Committee prior to study recruitment and data collection.  The study 
was explained to participants, questions invited, and signed consent obtained (see Appendix 
A).  Participation was completely voluntary and participants were free to withdraw from the 
study at any time or could decline to answer specific interview questions.  The consent form 
included an option to be contacted by the investigator to participate in a focus group 
following the completion of the semi-structured in-depth interviews and initial data analysis.  
Interview participants’ information was kept confidential as all data were de-identified and 
stored in a secure, locked environment. Only first names were used in the focus group to 
maintain as much confidentiality as possible in the group setting.   
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Prior to enrollment the investigator reviewed the informed consent form with the 
participant and confirmed eligibility for the study.  As part of this discussion, the investigator 
asked the participant to describe in their own words the purpose of the study and components 
of participation in order to assess the level of understanding.  In the event that the 
investigator was concerned that the potential participant did not understand the purpose of 
the research or what would be requested of study participants, then the participant was to be 
thanked for their time and interest in the study, but not enrolled.  This process for 
ascertaining capacity for consent is consistent with the procedure used within the KUMC 
Alzheimer & Memory Program (J Burns, Director, personal communication, October 30, 
2009).  Discussion with patients and careful review of the informed consent form to 
determine the capacity for medical decision-making also is supported in the literature (Jeste 
et al., 2003; Venesy, 1995).  
Recruitment. The Managing Director of the KUMC BCSC and designated staff 
assisted with the identification of eligible women.  Additionally, HCPs, i.e.: oncologists and 
oncology nurses practicing at the KUMC Breast Cancer Program, and members of the 
Greater Kansas City Chapter of the Oncology Nursing Society received a letter describing 
the study (see Appendix B) and a study synopsis outlining eligibility criteria (see Appendix 
C). HCPs were asked to recruit potential participants. A flyer was developed for use in 
discussing potential participation with eligible women (see Appendix D). The flyer was 
posted in the KUMC infusion center as well as the BCSC.  
Eligible patients receiving care and follow-up at the KUMC Breast Cancer 
Survivorship Center were invited to participate by the Managing Director of the Survivorship 
Center and her staff, oncologists and oncology nurses.  Women expressing an interest in 
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participation were provided with contact information for the investigator.  Women interested 
in participating in the study contacted the investigator and the investigator then discussed the 
study and confirmed interest and eligibility.  Initial contact between the investigator and 
potential study participants occurred by phone, e-mail or in-person.  Informed consent took 
place in-person at the BCSC or a location mutually agreeable to the participant and the 
investigator such as participants’ homes. 
Prior to initiation of data collection, efforts were made to further refine the interview 
guide by consulting two key informants who were women with breast cancer that self-
reported CRCI and were not eligible for the study. The key informants were identified by the 
Managing Director of the KUMC BCSC and the investigator.  Both women were more than 
12 months from completing chemotherapy. The first interviewee had previously participated 
in research related to CRCI conducted by the Managing Director of the KUMC BCSC. The 
second interviewee was known to the investigator through a previous introduction and had 
expressed interest in participating in the current study.  
Following informed consent by the investigator, the key informants were invited to 
provide advice related to the development of the interview guide.  The first informant was 
three years out from completion of chemotherapy and continued to report issues with CRCI 
such as difficulty with short term memory and word finding. The second informant had 
completed chemotherapy 15 months earlier and shared that she, her mother, and her aunt had 
experienced CRCI during and after chemotherapy for breast cancer. Both agreed the primary 
questions and probes in the interview guide were appropriately worded to answer the 
research questions. However, the second informant initially thought that “changes in memory 
and thinking” related to her worldview following the diagnosis of cancer and suggested 
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asking about “changes in memory” only. The first informant noted that she would have 
preferred to receive education about CRCI once her oncologist had confirmed a complete 
response to therapy. Both recommended interviewing women greater than 12 months from 
completion of chemotherapy due to the lingering sequela of fatigue and potential for lack of 
awareness of CRCI until all the other side effects of treatment and the concerns related to 
dealing with the diagnosis and treatment were reduced. The key informants confirmed the 
original guide was appropriate, so the original version was retained.   
Data collection. Data were collected over a period of six months. Demographic 
information were collected in the form of a questionnaire (see Appendix E) for all 
participants including: age at diagnosis, current age, marital status, ethnicity, menopausal 
status at diagnosis, current menopausal status, employment status at diagnosis, current 
employment status, level of education, stage of disease at diagnosis, time since last 
chemotherapy, chemotherapy regimen (agents, frequency, duration), and hormonal therapy 
status.   
The semi-structured interview guide was used to elicit information from participants 
through the use of open ended questions (see Appendix F).  The guide was revised based on 
information provided by key informants identified at the beginning of the study and results 
from on-going data analysis as new areas of questioning were identified.  The guide 
consisted of four primary questions and a series of related probes used to enhance participant 
response if needed.  The four open-ended questions were designed to stimulate a rich 
description of the experience of CRCI and participants’ views on desired timing and content 
of related education. 
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 The semi-structured in-depth interviews (approximately 60 minutes in length) were 
conducted at the KUMC Breast Cancer Survivorship Center or at a location of the 
participants’ choosing that was agreeable to the investigator, such as participants’ homes.  
Interviews were audiotaped and transcribed verbatim.   
 Upon completion of the interviews and initial data analysis, participants who 
provided consent to be contacted for follow-up were invited to participate in a focus group 
comprised of 5-8 women.  The purpose of the focus group was to provide the opportunity for 
member checking (participant feedback and validation) to assure that study results and 
interpretations from the data collected during the interviews were an accurate reflection of 
participants’ experience of CRCI and recommendations for education.   
 During the focus group, the investigator reviewed a summary of pooled responses to 
questions posed during the in-depth semi-structured interviews and the themes identified 
during the data analysis. Focus group participants were asked to provide feedback related to 
the summary and identified themes.  Samples of specific suggestions for educational content 
gleaned from the interviews were reviewed with the focus group participants. Feedback and 
validation was obtained. The feedback was used to further refine the description of the 
experience of CRCI, related educational needs, and specific suggestions for educational 
content. One focus group was sufficient to complete the member checking process based on 
the congruence of the initial analysis and interpretation of study results with the responses 
obtained from member checking during the focus group.  
The focus group was conducted in a conference room at the KUMC Breast Cancer 
Survivorship Center.  The investigator facilitated the focus group session (90 minutes in 
length).  Prior experience with focus group facilitation was gained by the investigator 
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through conducting focus groups for the Oncology Nursing Society Board of Directors 
(Krebs, et al., 1996).  Ground rules for focus groups participation were reviewed with all 
participants at the beginning of the session. Only first names were used to protect 
participants’ privacy as much as possible. Participants were instructed that information 
shared during the group session was not to be shared with anyone outside the group. 
Participants also were instructed to speak one at a time and to provide all participants an 
equal chance to speak during the session. The investigator encouraged participants to openly 
and constructively disagree with any study findings they did not feel accurately reflected the 
experience of CRCI or their recommendations for education. 
The focus group session was scribed by a graduate student from the University Of 
Kansas School Of Nursing. The scribe was prepared for assisting with the focus group by the 
investigator. The preparation included a review of pertinent literature, a discussion of 
rationale for focus group research, and a description of group facilitation techniques. 
Expectations for note-taking during the focus group session were reviewed. Selected 
recordings and transcripts of the in-depth interviews were shared and reviewed and initial 
data interpretations were discussed in preparation for the presentation of data to the focus 
group.  The investigator and the scribe performed an on-site assessment of the KUMC BCSC 
conference room to review the data to be presented, discuss seating, and test the recording 
devices to assure successful audio capture for the purpose of accurate transcription. The 
focus group session was audiotaped and transcribed verbatim.  The scribe’s notes were used 
as an aid for debriefing following the session as well as transcription of the audiotape. 
 Qualitative descriptive methodology is appropriate when seeking a thorough, in-depth 
description of an experience as well as investigating research questions that are of special 
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relevance to practitioners and for which the literature is limited (Sandelowski, 2000).  In-
depth interviews were selected as the qualitative strategy to answer the research questions in 
order not to limit participants’ responses.  The use of open-ended questions allowed 
participants to share information freely outside the constraints of a structured survey.  This 
strategy provided an opportunity to learn details of the participants’ perception of the 
experience of CRCI that may not otherwise have been shared.  Focus group participation 
provided participants an opportunity to validate their perceptions and experiences with other 
survivors.  Focus group responses were used as a mechanism for member checking to 
confirm the interpretations of the data obtained from the in-depth interviews and explore 
additional questions that were raised.  
Data Analysis 
Qualitative content analysis of participants’ audiotaped responses to the interview 
guide was used to analyze the data from the interviews to answer the research questions: 1) 
How do women who have received chemotherapy for breast cancer describe the experience 
of CRCI?; 2) What information about CRCI would women who have received chemotherapy 
for breast cancer have found helpful prior to initiation of treatment?; and 3) What 
information about CRCI would women with breast cancer have found helpful once changes 
in cognition are experienced?   
Data were simultaneously collected and analyzed in an iterative process designed to 
continuously modify the semi-structured interview guide, if needed, as new insights were 
acquired and new questions identified about participants’ experience of CRCI (Sandelowski, 
2000).  Field notes were used to supplement study transcripts. These notes facilitated the 
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inclusion of both manifest and latent content for analysis in order to ascertain the deepest 
possible meaning of the descriptions provided by participants. 
Inductive analysis procedures were used to prepare, organize, and report the data (Elo 
& Kyngas, 2007).  Transcripts were organized into meaning units (such as words, phrases, 
sentences, or paragraphs that conveyed like content deemed important to understanding the 
participant experience).  The meaning units were coded and grouped into categories.  NVivo 
8 qualitative software was used for the organization and coding of the transcripts (NVivo 8, 
2008 QSR International Pty Ltd.). The abstraction process continued until primary themes 
were identified (Elo & Kyngas).  Refinement of categories and themes continued throughout 
the member checking, peer and expert review process. Participants’ direct quotes were used 
as the data were analyzed and reported to provide a rich description of the experience of 
CRCI and recommendations for education prior to treatment and once changes in cognition 
were experienced. 
Credibility Assessment 
 The credibility of the qualitative content analysis was strengthened through the use of 
member checking, peer review, and data triangulation.  Member checking was conducted 
through the focus group held after the conclusion of the semi-structured in-depth interviews 
and initial data analysis.  
 Peer review was conducted with the focus group scribe as data from the in-depth 
interviews were analyzed.  The scribe conducted a quality check of a sampling of three 
audiotapes and transcriptions to verify accuracy. Results of the quality check were used to 
discuss the evolution of the investigator’s interview style to less talking and more listening. 
Selected transcripts were shared and discussed as coding was conducted and categories 
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identified. The scribe concurred with the categories that emerged as data were analyzed. 
Expert review was conducted with select members of the investigator’s dissertation 
committee who have expertise in qualitative content analysis. Initial interpretations were 
shared with the Dissertation Committee Chair prior to conducting the focus group. Suggested 
revisions were made to the presentation to enhance clarity and stimulate rich discussion of 
the results. The revised presentation and focus group participants’ comments about the 
investigator’s interpretations of the data were shared with one committee member who made 
suggestions to the development of overarching themes and the need to personalize the study 
results. Some wording was simplified, such as the revision of the use of the term 
“comparisons” to “feels like” for reporting results related to analogous experiences to CRCI. 
Quantification of the sample demographics and study categories was added.  
 Data collection procedures were supplemented by regular journaling of thoughts, 
feelings, observations, and insights by the investigator.  Journal notes were used to provide 
an audit trail as data analysis was conducted and decisions made related to identification of 
categories and themes from participants’ descriptions of the experience of CRCI and desired 
timing and content of related education. Field notes were recorded following each in-depth 
interview and the focus group.  Prior to data collection, the primary investigator documented 
preconceived notions about the patient experience of CRCI.  The investigator noted 
expectations that: 1) Women notice CRCI early in the course of chemotherapy; 2) Women 
want to have education about CRCI prior to initiating chemotherapy; 3) Women want to 
receive as much information about CRCI as possible; and 4) Women prefer the education 
about CRCI to be provided by an oncology nurse. This process served to identify biases prior 
to the start of the research. The investigator made a conscious effort to separate herself from 
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these ideas in an effort to be totally open to the information shared by participants. In 
particular, the investigator noted preconceived ideas about the timing of cognitive changes 
and women’s preferences related to receipt of education about CRCI. 
Limitations of the Study 
 Homogeneity of the sample related to the level of education may limit the 
generalizability of the study results. All but one participant were educated beyond the high 
school level. The experience of CRCI may vary for women with less education and 
potentially lower baseline cognitive function. Peer review was conducted with a non-
oncology nurse who served as scribe. The scribe was very familiar with the study so was in a 
good position to provide input on data interpretations. The scribe’s lack of oncology 
experience may have contributed to missing some nuances associated with the diagnosis of 
cancer. However this limitation may have been balanced by bringing a fresh perspective to 
the data. Coding was performed by a single investigator and was therefore subject to the 
biases and interpretations of one individual, although this was mediated by the expert-review 
and advice of the dissertation committee. 
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Chapter 4: Results 
 Eighteen women responded to the three primary questions in the interview guide: 1) 
How would you describe your experience with changes in thinking and memory during 
chemotherapy?; 2) What information would you have found helpful prior to starting 
chemotherapy?; and 3) What information would you have found helpful once you began to 
notice changes in your thinking and memory? These three primary questions in the interview 
guide were designed to answer the three research questions: 1) What is the experience of 
CRCI for women with breast cancer who have received chemotherapy; 2) What information 
about CRCI would women who have received chemotherapy for breast cancer have found 
helpful prior to the initiation of treatment?; and 3) What information about CRCI would 
women with breast cancer have found helpful once changes in cognition are experienced? 
The fourth primary question in the interview guide, “Is there anything else you would like to 
share about your experience?”, was used at the conclusion of each interview after the 
investigator performed a member check by verbally summarizing the major points discussed 
during the interview.  
 Qualitative content analysis was initiated immediately following completion of the 
first interview. The coding process began as the audiotape was transcribed and continued 
with each subsequent interview. Participants’ responses to the interview questions were 
grouped into meaning units and categories were assigned as patterns were recognized.  The 
iterative process of data analysis prompted additional member checking during the interviews 
to verify whether or not the descriptions of the experience of CRCI were consistent among 
participants. Due to the specificity of the research questions, data analysis and coding 
initially yielded two main themes that were congruent with the research questions and 
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consistent with the structure of the interview guide: 1) Experience of CRCI, and 2) 
Recommendations for Education. As the iterative process of data analysis continued, the 
frequency with which participants described various methods of coping with CRCI led to the 
decision to reflect Coping Strategies as the third main theme. Further analysis, with input 
from the results of expert review, refined the themes to more accurately reflect the personal 
nature of the experience of CRCI and the impact on participants’ lives.  
The overarching theme was identified as Life with Chemobrain. This theme 
encompasses all the participants’ descriptions of the experience of CRCI, the coping 
strategies they employed, and the education they would have liked to have received. The 
overarching theme is comprised of three subthemes. The first subtheme is Life with 
Chemobrain: How I Changed. Participants provided rich descriptions of the changes in 
cognition they experienced during and after chemotherapy for breast cancer. The first 
subtheme includes participants’ descriptions of how CRCI “feels” as well as deficits in short 
term and verbal memory, ability to focus, and ability to multitask.  The second subtheme, 
Life with Chemobrain: How I Cope, consists of participants’ descriptions of strategies they 
use to cope with changes in cognition such as systems of documentation for things to 
remember, focusing on one task at a time, allowing sufficient time to accomplish tasks, and 
giving themselves permission to make mistakes.  The third subtheme is Life with 
Chemobrain: How to Teach Me. Participants provided specific advice related to their 
preferences for the timing, content, and amount of education about CRCI. The underlying 
basis for their recommendations was the need for education to be individualized to account 
for differences in learning styles and the timing of participants’ educational needs. Details 
about the study sample and themes follow.  
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Sample Description 
 In-depth interviews were conducted with 18 women who were within 6-12 of months 
of completing chemotherapy. Ages ranged from 26-61 (see Table 4).  Sixteen participants 
were married and two were divorced. No changes in marital status occurred since participants 
were diagnosed with breast cancer. The sample was comprised both of Caucasian (15) and 
African American (3) participants. Prior to chemotherapy 12 women were premenopausal.  
After chemotherapy only 4 were still menstruating. The majority of the sample worked full 
time. One participant changed to part time status during treatment and three were not 
presently working, two of whom attributed loss of employment to cognitive changes.  
Participants were well educated.  Most of the women were diagnosed with stage II breast 
cancer, although all four stages of disease were represented in the study. The primary 
chemotherapy regimen was Adriamycin® (doxorubicin) and Cytoxan® (cyclophosphamide), 
followed by Taxol® (paclitaxel) (n = 12) or Taxotere® (docetaxel) (n = 5). Five received 
Herceptin® (trastuzumab) in addition to the primary regimen. Two also received Avastin® 
(bevacizumab). Other regimen components included Xeloda® (capecitabine) (n = 1), and 
Abraxane® (paclitaxel protein-bound particles for injectable suspension) (n = 1). One 
woman could not remember the names of her chemotherapy agents. The duration of 
treatment ranged from 4-8 months. Participants’ responses regarding the frequency of 
chemotherapy administration were too varied to summarize due to the wording of the 
questionnaire and some uncertainty on the part of participants about how to answer this 
question as many of them had received more than one regimen with varying levels of 
administration frequency. Reported menopausal symptoms included hot flashes, trouble 
sleeping, weight gain, and feeling irritable. Over half the sample continued to experience  
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Table 4 
Participant Demographics, N = 18 
Category   n  Category   n 
 
Current Age     Marital Status 
__________________________  ___________________________ 
 
25-30    3  Married   16 
31-35    1  Divorced     2 
36-40    3 
41-45    3  Ethnicity 
      ___________________________  
46-50    1 
51-55    5  Caucasian   15 
56-60    0  African American    3 
61-65    2 
 
Job Status*     Education Level 
__________________________  ___________________________ 
 
Full Time   11  High School     1 
Part Time     2  College   11 
Not Working     3  Graduate School    6 
Homemaker     2 
Lost job     2  
*Participants could select more than one response 
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Table 4 Continued 
Category   n  Category   n 
 
Stage at Diagnosis    Hormonal Therapy 
__________________________  ___________________________ 
 
I     4  Yes    10 
II     8  No      8 
III     3 
IV     1 
Not sure    2 
 
Menopausal Status Pre-Treatment  Menopausal Status Post-Treatment 
___________________________  ____________________________ 
Pre    12  Pre      4 
Post      5  Post    12 
Peri      1  Peri      1 
Not sure     0  Not sure     1 
 
Menopausal Symptoms*   Other Symptoms 
___________________________  ____________________________ 
Hot flashes     6  Anxiety     7    
Trouble sleeping    8  Depression     6 
Weight gain     5  Fatigue   10 
Feeling irritable    2 
*Participants could select more than one response 
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fatigue following the cessation of chemotherapy while about a third noted anxiety or 
depression.  
 Life with Chemobrain: How I Changed 
 Participants provided poignant descriptions of the many changes in their lives 
resulting from CRCI. Participants’ descriptions of these changes were coded into seven 
categories including: deficits in “short term memory”, trouble with word finding (verbal 
memory), “lack of focus” and decreased executive function, decreased performance, “It feels 
like…” (analogies of how CRCI “feels”), other physical factors, and the trajectory of CRCI. 
Participants’ own words were selected as examples for each category and the quotes are 
provided in Table 5.  
 Deficits in “short term memory”. Nine participants acknowledged a significant 
change in their short term memory. Deficits included difficulty retaining information in a 
variety of settings such as casual conversation with friends or family, work or school related 
activities, and reading or movies.  Participants described frequently finding themselves in a 
room and not remembering the purpose for being there.  Several participants noted frequently 
misplacing items such as cash, keys, and cell phones. One young woman shared: 
 I put a 20 dollar bill somewhere the other day and for the life of me I can’t remember 
where I put it. I mean I had it in my pocket and it’s like, well, it was going to fall out 
when I went for a run and I slid it somewhere. It’s in my house and I’m going to find 
it someday and it’s going to be great. I tucked it underneath something. And I don’t 
remember what I did with it.   
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Table 5 
Select Quotes for Life with Chemobrain: How I Changed Categories 
 
Category  Quote 
 
Deficits in short 
term memory  
Yeah…not so much long term, but more recent…short term…So 
even to the kids, like….did you brush your teeth? And you know, 2 
minutes later, did you brush your teeth? Like I couldn’t remember, 
did you say? You know, and my kids would say I answered you 5 
times!  And I’m like… so sorry, I do not remember hearing you 
….I don’t remember asking and I don’t remember hearing you 
answer (chuckling). 
 
And it was more a short term memory thing? I could remember 
something that happened in the previous calendar, school year, 
somebody who’d visited or applied, or went through the process but 
I couldn’t remember if I’d sent someone a contract or if I had done 
this step in the process.  
 
Trouble with word 
finding (verbal 
memory) 
 
And that’s part of memory. I mean you’ve got your vocabulary 
stored but if you can’t….I’ve noticed myself saying in the last few 
weeks when I’m on tours I can’t think of the word I wanted to use. 
And I’ll say …we’ll stop and be like…uuuhh, like tongue-tied kind 
of. Fumbling for a word, and then I’ll figure it out. And I’ll feel 
kind of stupid, cause I’m not that way, I haven’t been that way. But 
when I was going through chemo we had a joke, I’d always say, 
chemobrain, chemobrain today. Don’t trust what I’m saying 
because it’s chemobrain. Um, and I think that’s definitely, for me, 
I’m a very verbal person and to not be able to come up with the 
word is very frustrating and it feels awkward.  
 
So after talking with somebody for awhile I start losing words. I 
can’t finish my thought. And I’m a fairly verbal person. And people 
that know me will say …I talked about anybody, I enjoy 
…sometimes the words just don’t come.  
 
Lack of focus and 
decreased 
executive function 
 
I’ve always been a reader. And I used to like be able to read even, 
you know, like thrillers or mysteries and stuff and now I just stay 
on…and it took me (sighing) boy you know I did books on…..and 
I’ve always used to enjoy books on tape, or CD or whatever…but I 
did ONLY those probably for a year because I couldn’t concentrate 
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or focus on reading a book, you know  I couldn’t sit down with , 
even, like a simple little romance novel and focus on reading it. I 
couldn’t do it.  
 
Yeah…I mean you know and I would lay in bed, and it’s like I 
couldn’t even watch TV you know, I couldn’t even concentrate on 
the TV  
 
And then I’ll really lose my focus because when that happens I just 
feel like I said, I could be in a conversation and here talking to you 
but yet I’m not a 100% there.  
 
I get lost a lot easier driving (chuckling). I have two GPS’s. This is 
funny, it actually happened this morning. I have two GPS units. I 
have a GPS and one on my phone and I typically take printed 
directions with me now also and I could not find where I was going 
to a meeting this morning. 45 minutes later I finally figured out 
where I was supposed to be. And at that point I had missed the 
meeting (laughing). 
 
Sometimes I’m driving and then I’ll …I won’t remember …oh I 
already went through that intersection or, you know there’s like a 
blank moment of…where am I going? (laughing) you know…oh 
right….that’s what I’m doing…you know.  It’s not like you’re 
completely unsafe in the car, it’s not that, it’s just you may be…it’s 
the same process of where you might be running upstairs or 
downstairs and then all of the sudden you can’t remember what it 
was that I was doing and ….it’s sort of the same thing, but you do 
notice it in the car…which I would never have done before. 
 
I’ve caught myself lately …when I go through an intersection, I 
look around and I think did I look at the light to be sure it was the 
right color before I went through the intersection? And it’s all part 
of that sort of relearning how to drive. Relearning what was 
automatic to me before is not. And sometimes, I don’t think like 
speeding is an issue but it’s more just the general operation of the 
car. I’ll just be like, I’m on the road now, I need to remember that 
there’s a stop light or I need to put my blinker on to turn, or am I 
turning into the right lane so, it is a lot of those common things that 
you think you have ingrained in you that are sort of fuzzy. And it’s 
not like I think I can’t drive but I do notice myself catching myself 
and I’ll look .....my reaction time is different. I think that’s true. 
You know when you’re watching a stop light and where as I might 
have gone when it turned green, now I’m sort of Ok….look 
around…be sure we all have the same signal here, we’re all doing 
the same thing. I’m going to go, you’re stopping,. But it’s very 
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strange. Now that I think about it. And, my daughter is old enough 
to drive and she’s been driving me to school and I feel so much 
more comfortable sitting and being a passenger.  
 
I had 2 chemo treatments and it was a day of treatment and my hair 
was starting to fall out and um, I was…I got off the highway to go 
to McDonalds to grab a little something to eat. And I was sitting at 
a stop light and was looking this way for merging traffic (looks left) 
and I thought that I was stopped but I wasn’t and I hit the person in 
front of me. And (inhales audibly) so that was just like you know 
like even, um, knowing if I was moving or not. You know like I 
couldn’t …I couldn’t tell that I was moving. 
 
Decreased 
performance 
 
Well…even when I started chemo…and I was trying to work…um, 
it was pretty much…really what consisted of my work was going in 
one or two hours and trying to think of what I hadn’t like shown 
somebody what to do, you know? And um, (sighing) it was um, 
kind of difficult while being on the chemo to go through a full 
thought process. Um, and um, then, you know for those 3 months 
there were things that I would forget to do at work now whether 
that was chemo related or hysterical related or whatever you 
know…but like I forgot to pay, like, a certain tax or whatever. They 
used that against me to fire me.  
 
I was very aware that was going on …I couldn’t remem…I’d go out 
to you know…if somebody would make an appointment and I’d 
start pulling things ..couldn’t remember sizes, couldn’t remember 
what they said they wanted. Let’s see did they say wanted that, or 
didn’t want that. You know, that kind of thing. It really impacted 
the job. 
 
“It feels like”…. 
 
It was like being pregnant and just not, um, I just felt like I was 
pregnant again. And it’s like, it’s frustrating. Just not being able to 
remember, uh, things slipping by, uh, you know somebody tells you 
a date and not being able, several days later being clueless that they 
even told you that date. It’s um, just no recall.  
 
I would relate it to being pregnant …maybe, you know like um you 
know, like I said I was sharing my brain. You know with the fetus? 
(chuckling) And you know doing, just not able to pay attention to 
everything and forgetting things. 
 
Other physical 
factors 
 
Fatigue 
 
Especially when I was so sleep deprived. So, um, but, like, I 
couldn’t think about putting together a grocery list or you know, 
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like that was way beyond my capability.  
 
Um, I mean when I was exercising I was feeling better, and so my 
memory was better. So I don’t know that it was linked to exercise, I 
just think it was linked to how I was feeling. Um, so, I can’t say 
that it was exercise related. And there were many times that I would 
have wished that I could have exercised but I couldn’t have gotten 
out of bed. So…. 
 
Yes, excellent. Although I will say, maybe it was memory and just 
the level of exhaustion to maintain friendships is real hard because 
you have to expend the energy to do it and unless people ….the true 
friends are still there. The people that are kind of on the periphery 
are like ….yeah. But that’s probably the fatigue.  
 
Well, I think it’s related first to fatigue, its’ definitely is fatigue and 
as your body’s going through that change of that chemical going 
through your body, and then I think eventually your lack of focus, 
your lack of memory starts occurring and you know if you’re not 
reading the news or you’re not reading a book you’re not going to 
remember things ....so I think it’s a buildup effect of losing that 
process... 
 
Um, so, but I do think it is improving as far as my memory, word 
finding, and things like that. Except when I’m tired.  
 
Clumsiness and decreased balance 
 
I’ve noticed a great lack of coordination. I can’t stand on one foot 
to put on pants or put on shoes or, without leaning up against 
something ….balance….I have always been very coordinated. I 
have considered myself athletic. It irritates the heck out of me that I 
can’t do that.  
 
I don’t remember ever falling down this much as I do. I uh, and 
dropping things. I routinely drop things. And it’s one of those 
moments where you go, I swear I had a grip on that. I swear I had 
that in my hand. How did…how did that fall? But…um, and some 
days more than others I’ll have very full clumsy days. And one 
thing I’ve found that …and I don’t know if this has any relation 
whatsoever, but looking at days where I’m nutritionally better…I 
eat more protein um, I drink more water …I’m clearer and feel 
better in general and I’m not nearly as clumsy. So I have no idea if 
that’s related but it also coincides with feeling more energetic and 
able to get to the gym, and run a little longer on the treadmill 
and….so I have no idea if nutrition would help on that level or if 
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it’s just that you’re giving yourself more energy and…. 
 
Neuropathy 
 
I worry now because I have this weird, when I touch my fingers 
sometime….it hurts (touching left pinky). Have you heard of that? 
It’s more pain. I know people say numbness and tingling… 
 
I lost all these down to here (indicating fingers) and then my toes, 
they had to dial everything back towards the end cause …and I had 
to fight with them for it cause you know if it gets too far, it won’t 
regrow. I mean that’s part of the reason I wasn’t super active cause 
my feet were so numb that it felt like your toes were curling under. 
That’s what it felt like ….it actually hurt. My fingers were always 
cold and numb but my feet actually hurt. And so they dialed my 
taxol back towards the end and then I was on Neurontin to try to 
help try to stimulate the nerve growth which I haven’t got all mine 
back. I feel like sometimes lose a little bit in my thumbs, a little 
sensation but I know that some people never get that back either. 
 
 
Trajectory of 
CRCI 
 
Uh, you know I think because your going through treatment you’re 
in such a fog anyway. Um, you’re feeling 50-60% of normal that, I 
don’t know….and I wasn’t working as regularly. I didn’t pay as 
much attention to whether I was on top of things and I was 
forgiving myself a lot of thing I normally…..sleeping more all those 
kinds of things. So I just didn’t really pay attention to how on top of 
it I was. So I have to say, it probably wasn’t until I was completely 
done with treatment that I really began noticing it. And then I kind 
of thought, well….I’m still getting a lot of drugs, but I’m really 
realistic. But I think it really was more after treatment was done.  
 
Uh, definitely during, uh, probably…..gosh, probably after I’d had a 
couple treatments, so 3…3 maybe 4 weeks in. 
 
No, not really.  Jennifer told me I would probably start to see some 
improvement after a year.  I’m waiting! 
 
I feel like they’ve gotten better. Um…I mean it…I could just 
remember things like what’s on the grocery list or what are we 
doing this weekend.  Those sorts of repetitive conversations …did I 
really say this?  Or did you tell me that? Or like my husband and I? 
We have a lot more of those conversations it seems like. Last, um 
associated with date, last August or September that’s kind of when I 
would have been right at…it seems kind of like it has slowed down 
a bit. Uh, I seem to struggle the most with things here at work. But 
again that’s more associated with longer timelines.  
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I think just being patient with yourself you know related to the 
memory loss ….I think I’ve noticed that um, it has kind of resolved 
itself over time. And the instances are getting further and further 
apart. So I’m still hopeful that eventually it’ll just go away. Um, 
but, now that I think about it the work that I’ve been trying to do 
and hearing my boss, or my husband or whoever say, it’s ok you 
know. It’ll go away. Be patient and many, many times I’ve kind of 
watched that process. And looking back , now I’m done! Now it’ll 
all go away. …..But it doesn’t happen that way. And logically I 
know that now you just kind of lose that perspective for a little 
while.  
 
I feel like the longer it’s been, it seems to happen less often. Um, 
but then when it does, like just this morning …uuuhhh, I thought 
this was getting better. You know and every time it happened I’m 
like   UURRRHH (clenching hands).  
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Another participant noted, “I was at a conference yesterday. I couldn’t begin to count the 
number of times I misplaced my cell phone or the number of times I had to completely empty 
out my purse to find it”.  
Participants were unable to remember appointments, tasks they needed to do, or items 
from conversations without writing things down. One example follows: 
When someone tells me something like at work, I really have to….you know I have 
to write things down. ‘Cause if I don’t, two minutes after they told me what they 
wanted me to do, a lot of times I can’t remember.  
 Trouble with word finding (verbal memory). Complaints of word finding occurred for 
100% of the sample population. Participants described “forgetting names, not completing 
sentences” and “not being able think of the word”. One participant shared a story about 
preparing dinner for the family: 
My aunt called and said, well what are we having? Um, I don’t remember. So what 
are you making? Well, I know what I’m making I don’t remember what it’s called. 
But I know how to make it. And I can’t remember what we’re having. Imagine how 
stupid that feels! You know, we were having Swedish meat balls!  That’s what it was!  
But, I couldn’t remember what we were having. 
 “Lack of focus” and decreased executive function. Nine participants described being 
unable to focus or concentrate, contributing to issues such as maintaining their train of 
thought in conversation. Six participants described lapses in focus and decreased executive 
function contributing to issues with driving familiar routes and in other various aspects of 
driving such as coming to a complete stop at intersections, correctly responding to traffic 
signals, and the necessary steps to refuel the vehicle.  Another example of decreased 
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executive function involved inability to follow a recipe when cooking. Additionally, one 
participant’s husband has taken over handling the bills (the process of writing the checks, 
stamping, and mailing). She described herself as “not trustworthy enough to do it” and that 
her husband “wasn’t sure where the bills would end up”.  
Several participants mentioned losing the ability to multitask and/or the need to focus 
on one thing at a time. When referring to cooking, one participant noted: 
I mean… because I’m slower at it for physical reasons and I used to be able to 
like…you know, do 3 or 4 different things at a time in the kitchen, but now I got to do 
one thing at a time. ‘Cause I have to focus on it. 
 Decreased performance. Two participants indicated that cognitive changes 
contributed to the loss of employment.  One of these participants historically had worked >60 
hours a week as a company comptroller and was the “go-to” team member for problem 
resolution due to her organizational skills and ability to balance multiple activities.  Now, she 
describes looking at the job descriptions in the newspaper and struggling to find the type of 
employment where she would have a one-focus job.  The second of these participants worked 
in a retail position as a personal shopper.  Subsequent to her changes in cognition she 
described being unable to remember her clients’ preferences, sizes, or previous requests for 
merchandise.  One young woman working on her master’s degree described herself as having 
a photographic memory prior to chemotherapy.  She related never having to read something 
more than once and maintaining an A average in her classes.  During chemotherapy she had 
to drop a class as she could no longer succeed with her current pattern of study habits.  She 
maintained an A in the class until beginning treatment but subsequently was at risk for failing 
the class due to her inability to retain information from reading and class work for the 
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examinations during and after treatment.  She has adapted her study methods and is now 
maintaining a B average.  She described having an extensive vocabulary and expressed 
significant frustration at not being able to think of the words she wants to use in expressing 
herself.  She, as well as other participants in the study, described the use of word substitution 
in order to maintain a conversation.  This same young woman indicated she never needed to 
write down appointments prior to therapy.  She said she could remember her own, as well as 
her mother’s and her children’s appointments without difficulty.  However on the day of her 
scheduled interview for this study she admitted having no recollection of having scheduled 
the appointment and actually was not dressed or expecting anyone to come by. Participants 
noted that overall speed of performance was slowed due to the need to read things several 
times and changes in their processing speed. 
Some differences existed between whether participants found work or casual settings 
to be more problematic for their performance.  One participant noted that she had the most 
difficulty in casual conversation.  She described being focused and “on-point” during 
business interactions as she was using a good deal of energy to stay focused on the task at 
hand.  In a more social or casual setting she found herself to be more relaxed and therefore 
less focused.  Most participants described the greatest difficulty with short term memory and 
word finding in situations in which they were stressed or anxious. Focus group participants 
noted “taking longer to get things done at work” due to the need to read things multiple times 
and “slower thinking”.  
 “It feels like....”. A very rich component of participants’ descriptions of the 
experience of CRCI was what CRCI “feels like”. Participants described the experience of 
cognitive changes to be analogous to being pregnant, drinking too much, or the effects of 
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heavy allergy medicine.  Comparisons were made to aging as well as the cognitive changes 
associated with Alzheimer’s disease.  Complaints included feeling like one’s grandmother or 
someone’s “daffy old aunt”.  One participant described a strong family history of 
Alzheimer’s and expressed the fear that the cognitive changes she was experiencing now 
would predispose her to an earlier onset of Alzheimer’s in the future.  Another participant 
related her experience to the female protagonist in the movie “Mr. and Mrs. Bridge” in which 
the character is seen sitting in the car in the garage without a clear notion of what to do next. 
This participant described pulling up to the gas station to refuel her vehicle and having no 
idea how to release the gas cap.  She described sitting in the car for 15 minutes before she 
was able to remember the steps involved.  She said this happened to her on two occasions.  
She referred to the experience as “pulling a Mrs. Bridge”.  Participants also used the term 
“fog” to describe the feelings of being unable to think clearly and expressed frustration at 
feeling stupid.  
  Other physical factors. As participants described the experience of CRCI, a number 
of other physical factors consistently were discussed. Most women (72%, n = 13) described 
experiences with fatigue during and after treatment and 55% (n = 10) described ongoing 
issues with fatigue. Participants acknowledged that cognitive issues were more pronounced 
when they were tired and noted some improvement in mental clarity after napping or “getting 
enough rest”. 
Clumsiness and decreased balance was an issue for almost a third of the participants 
(27%, n = 5). Participants described no longer being able to stand on one leg to put on a sock, 
losing their balance going down a slope, dropping things and stumbling more than they used 
to do.  Almost half (44%, n = 8) of the participants had experienced neuropathy in their feet 
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(n = 2), toes ( n = 4), fingers ( n = 4) or fingers/toes ( n = 2) and 27% (n = 5) still had some 
residual numbness.  However, only one participant with residual neuropathy complained of 
clumsiness or balance issues (see Table 6). 
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Table 6 
 
Comparisons of Physical Factors and Other Reported Symptoms (n = 18) 
 
 
Age Anx Dep Ftg Sleep Neuro 
Ever 
Neuro 
Now 
Neuro 
Loc 
Clum/Bal Total 
 
 
61    X X X Toe (rt 
great) 
X 4 
61 X X X  X  Feet  4 
55 X  X  X X Fingers  4 
52     X  Feet  1 
52   X     X 2 
51   X X     2 
51         0 
48 X X X      3 
45 X X X X    X 5 
45   X      1 
41  X  X     2 
40 X  X X     2 
37    X    X 1 
37   X X     4 
35     X  Fingers/
Toes 
 2 
28     X X Toes  2 
27 X X X X X X Fingers/
Toes 
 6 
26 X X   X X Fingers X 1 
 
Total 7 6 10 8 8 5  5  
 
 
Anx = Anxiety, Dep = Depression, Ftg =  Fatigue, Neuro Ever = neuropathy during and/or 
after treatment, Neuro Now = neuropathy now, Neuro Loc = location of neuropathy, 
Clum/Bal = Clumsiness and/or Balance issues 
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Trajectory of CRCI. Variability was noted related to participants’ perceptions of when 
they began to notice cognitive changes. Most participants noticed changes during 
chemotherapy with the majority of these being after 1-2 months of treatment.  One 
participant described noticing changes immediately after receiving her first treatment.  Three 
participants did not notice changes until after therapy.  One of these women noticed changes 
4-5 months after completing chemotherapy and one did not notice changes until several 
months later.  
Most participants described noting some improvement in their cognitive changes over 
time. Some women mentioned beginning to notice improvement one to two months 
following the completion of chemotherapy. Word finding, however, appeared to be the 
primary residual deficit, with all participants complaining about this problem at the time of 
the interviews. Five (27%) of participants noted that improvement may have been hampered 
by recovery from subsequent surgeries after chemotherapy related to breast reconstruction 
and the effects of anesthesia. One woman’s quote reflecting the effects of anesthesia on 
cognition follows: 
Um, well I had my surgery after chemo and so I went right from chemo treatment 
into, and then I did a double mastectomy and um, and so I had, you know, from that 
um anesthesia, you know and all that in my body I was, you know, it took a long time 
to get out of that kind of funk. So, um, so I would say maybe …maybe like Julyish I 
was feeling pretty normal and feeling good, and exercising again and all that. And 
then in August I had my final surgery, my reconstruction surgery. And um, and so 
then um, it took me awhile to get over that anesthesia too. And so I think I probably 
started feeling normal again um, probably a couple months after that.  
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 Participants’ descriptions of the experience of CRCI (Life with Chemobrain: How I 
Changed) were consistent. The investigator began to note data saturation around the tenth 
interview related to complaints about short term memory, lack of focus, and decreased 
executive function. All of the participants complained about issues with word finding and a 
significant percentage experienced difficulty with reading and driving. Participants expressed 
concern about decreased performance at work and school, with two participants attributing 
loss of employment to CRCI. Comparisons of CRCI to “being pregnant” or exposure to 
substances such as alcohol or allergy medicine provide a potent description of what CRCI 
“feels like”. The other physical factors of residual fatigue, clumsiness/decreased balance and 
neuropathy are important in understanding the impact of CRCI on participants’ daily lives 
and raise a number of research questions for exploration. The trajectory of CRCI was 
variable, however most participants did experience some improvement over time.  
Life with Chemobrain: How I Cope 
 Participants described coping with the effects of CRCI in a number of ways. Primary 
coping strategies included: writing things down, importance of support and validation, 
helping others, depending on others, focusing on one task at a time, not rushing, and giving 
oneself permission to make mistakes. Participants also described attempts at intervention for 
CRCI including exercise, mind stimulation, getting enough rest, meditation/yoga, and good 
nutrition.  
“Writing things down”. The most common strategy described for coping with 
changes in memory and thinking was writing things down (see Table 7).  Participants varied 
slightly in the method they selected such as the use of phone calendars, day planners, 
notebooks, lists, and sticky notes.  However almost everyone (88%) described the need to  
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Table 7 
Life with Chemobrain: How I Cope Categories 
Category        n  % 
Coping Strategies 
_______________ 
Writing things down       16  88 
Importance of support       15  83  
Helping others          9  50 
Depending on others         7  38 
One task at a time         3  16 
Not rushing          3  16 
Permission to make mistakes        2  11 
 
Intervention Strategies 
___________________ 
Exercise          5  27 
Mind stimulation         5  27 
Getting enough rest         3  16 
Meditation/yoga         2   11 
Nutrition          1    5 
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make note of things they wanted to remember shortly after receiving information due to their 
difficulties with short term memory loss.   
Importance of support and validation. Most participants acknowledged the 
importance of the support of family, friends, and coworkers.  In general, participants 
described the reactions of others to the cognitive changes to be that of patience and 
understanding.  However a few participants did share that family members (such as husbands 
or children) expressed frustration at having to frequently repeat themselves due to the 
participant’s inability to retain information.  
One participant discussed the need for validation of her cognitive changes by her 
spouse. She expressed frustration that her husband didn’t acknowledge the difficulty she was 
experiencing.  She was one of the three participants who compared CRCI with the cognitive 
changes experienced during pregnancy.  As she and her husband have five children, she 
noted that the cognitive changes she experienced during and after chemotherapy might seem 
“normal” to her husband since she had been pregnant so much of their married life.  
Younger participants noted dealing with very different issues than most of the women 
they encountered in the infusion room and therefore requested a different type of support. For 
example participants in their 20’s and early 30’s expressed a desire for being matched with 
someone their own age as a support mechanism (age-matched support). Younger participants 
noted concerns about fertility and finding a mate. These issues were not a concern for older 
survivors and contributed to a lack of connection and support from other survivors.  
During the course of the interviews, participants expressed frustration at the lack of 
communication and validation by HCPs. As a result of the interviews, participants exhibited 
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enthusiasm for research being conducted to learn more about CRCI and noted a sense of 
“relief” that others were experiencing similar issues. 
Helping others. Several participants indicated a strong desire to help others through 
their experience of chemotherapy.  Some wanted to volunteer in infusion rooms to provide 
inspiration to those just starting treatment. Others wanted to start a support group in their area 
or develop a mechanism to provide meals to newly diagnosed women receiving treatment. 
Participants described the desire to “give back” and to “make something positive” out of their 
experience with breast cancer.  
Depending on others. A few participants described depending on their spouse, 
children, or coworkers to help them remember certain things.  One participant mentioned the 
need to tell coworkers what she had accomplished at the end of the day.  
I couldn’t remember if I’d sent someone a contract or if I had done this step in the 
process. And so I was leaving myself sticky notes. And every day, it was kind of a 
joke in our office. We’re all very tight knit. But every day I would leave and I would 
say I need to tell you these things in case I get hit by a bus tonight. But I think really 
what I was doing was I needed to tell somebody else what I had done so I could say 
to her, did I do that? 
One task at a time and not rushing. Focusing on one task at a time was mentioned by 
several participants as they described a decreased ability or inability to multitask compared to 
their ability prior to chemotherapy. Taking one’s time and not rushing were mentioned as 
strategies to increase success at completing tasks. One participant described a situation where 
she was cooking dinner when one of her kids came into the kitchen and needed to have a 
permission note to attend a field trip the next day. The participant said she had to delegate the 
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rest of the meal preparation to the other children because she could not work on both tasks at 
the same time. She acknowledged that multitasking was not difficult for her prior to 
chemotherapy. Establishing achievable deadlines for a task was one method mentioned for 
preventing a rushed timeline.  
“Permission to make mistakes”. Participants varied in their reaction to cognitive 
changes as some expressed more distress (complaints of feeling frustrated or upset) than 
others at not being able to find words or remember things.  One participant shared that she 
didn’t get stressed out over not being able to remember things because everyone makes 
mistakes.  She described an overall life philosophy of not worrying too much about things 
she couldn’t control.  Another participant advised women not to “stress about it” when they 
“mess up”. “Life’s too short and you’ve just got to move forward”. Others expressed a higher 
level of frustration at on-going cognitive issues and appeared to exhibit more distress. 
Exercise. Exercise was mentioned as an important interventional strategy by eleven 
(61%) of the participants.  However, only a few participants were able to exercise during 
treatment. Those who described returning to exercise following treatment indicated a 
perception of benefit to cognitive function (n = 5). Others acknowledged that the reduction in 
fatigue that allowed resumption of exercise may have contributed to cognitive improvement. 
One participant described the benefits of leaving the work setting to “work out for 30-60 
minutes” allowing her to return to her job with more mental clarity.  
Mind stimulation. Many participants recommended initiating efforts to “stimulate 
their mind” such as sudoku, crossword puzzles, or other “brain teaser” activities. Despite the 
difficulties with reading participants recommended trying to read some each day as a way to 
“work their brain”. 
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“Getting enough rest”. Association between cognitive changes and fatigue was 
mentioned frequently.  Participants described the need to get enough rest or take short naps 
during the day to sharpen their mental acuity. One participant shared that she was thankful 
she worked from home. The autonomy allowed her the flexibility to rest for 30 minutes when 
she needed to “sharpen her focus”.  Another participant described the need to “power nap” 
during the day as she would become so fatigued during social interactions that she would “hit 
a wall” and need to rest due to mental “fogginess”.  
Meditation/yoga. Additional strategies suggested to assist with focus were meditation 
and yoga. The one participant who suggested meditation as a strategy reiterated the idea 
during the focus group session. However, she acknowledged she had not yet tried meditation 
herself. Yoga was mentioned by another participant who enrolled in a class to help her with 
coordination and balance.  
Nutrition. One participant described being able to exercise more and “feeling clearer” 
when she ate more protein and stayed hydrated. 
Life with Chemobrain: How to Teach Me 
 One third (33%, n = 6) of the participants were told about the potential for cognitive 
changes during or following chemotherapy by members of their health care team prior to 
receiving therapy.  Participants were adamant about the need to know about this potential 
side effect up front.  Frustration was described as “feeling like they were going crazy” when 
cognitive changes began to occur for which they were unprepared.  However, one participant 
recommended waiting until near the end of treatment to discuss cognitive changes due to the 
major issues that women are coping with at the beginning of treatment such as fear of dying, 
loss of their breast(s) and the risk for cardiac damage from anthracyclines.  
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The primary basis for participants’ recommendations for education related to 
chemobrain was the need for individualized care.  Variation was seen in the extent of 
information that was desired as well as the delivery method. Participants were divided 
between wanting extensive information as early as possible so they could make appropriate 
plans and begin to assimilate the information, versus those who preferred very brief, general 
information. Five participants described being overwhelmed with the volume of written 
information that was provided about chemotherapy and side effects prior to treatment.  One 
woman described her experience in receiving a bag of booklets and pamphlets from her 
surgeon, medical oncologist, and radiation oncologist. As a result, she read very little of the 
information that had been provided.  Eight participants expressed the desire to have someone 
sit down with them and assess how they preferred to learn and their readiness to learn.   
Participants did not identify any one person on the health care team whom they felt 
was the best suited to provide the information.  However, they described wanting someone 
who was not rushed with whom they could spend enough time to gain comfort in asking 
sensitive questions. One participant suggested that education specialists be used so the 
variation in adult learning styles could be accommodated. Focus group participants stated 
that the ideal person to fill this role would be a cancer survivor, so that the person providing 
the information would have firsthand knowledge of the experience and would approach the 
topic with great sensitivity. They also recommended that the person be assigned at the 
beginning of treatment and maintain the relationship throughout treatment and subsequent 
follow-up. The benefit of a consistent relationship with an individual who “knew them” and 
was skilled in education was noted to be of great value.  
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One participant described wanting not to be treated only as a patient but to be 
recognized and acknowledged as an individual for whom the diagnosis and treatment would 
have an impact on her day to day life.  Several women noted that the paradigm of the 
treatment milieu de-individualized the person being treated due to the need to put their lives 
and schedules on hold to fit into the schedule structure imposed by the treatment facility. 
 Participants shared their thoughts on the educational content and style they would 
have found beneficial. Suggestions included providing a simple one page handout with large 
font and no medical jargon. A compilation of pertinent statements from participants for the 
description of CRCI to women preparing to start chemotherapy was validated by the focus 
group and is summarized in Table 8.   
 Participants wanted a description of the likely cognitive changes such as trouble with 
short term memory, and trouble with word finding.  They wanted to know what was meant 
by cognitive changes.  As one participant joked, “Does it mean that I’ll roll over in bed one 
morning and not recognize my husband? What does it really mean?” 
 Information for spouses and children was desired.  Many participants discussed the 
lack of information geared to describing CRCI for their family members and felt that 
education was important in order for the family to anticipate and understand CRCI. 
 Recommendations included suggestions to reconsider taking classes during 
chemotherapy or to be aware that existing study patterns or test-taking skills may be affected. 
Participants desired information on the incidence and duration of CRCI as well as any 
information about effective interventions.  A number of suggestions were made regarding 
inclusion of ideas for coping strategies. Participants’ recommendations related to educational 
content were validated with the focus group and are summarized in Table 8.  
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Table 8 
 
Recommendations for Education about CRCI 
Category 
 
Suggested Statements to Describe CRCI 
___________________________________ 
 
Some women have experienced memory changes during and after receiving 
chemotherapy. 
 
These changes have been compared to the type of memory changes experienced during  
pregnancy or when taking allergy medicine. 
 
Some women describe feeling as if they were in a fog. 
Not all women have this experience, but those who do describe issues with short term  
memory and difficulty finding the right word. 
 
Others have described difficulty with driving and sense of direction, following written  
instructions (like recipes), or maintaining focus when reading.  
 
Many women experience improvements in memory and thinking over time.  
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Table 8 continued 
 
Recommendations for Education about CRCI 
Category 
 
Suggested Recommendations for Educational Content 
____________________________________________ 
 
 
Choose a method of writing down important things or activities you want to remember 
such as a notebook, day planner, or phone that you keep with you at all times. 
Get enough sleep to feel rested (this may include naps). 
Start or maintain activities to stimulate your mind such as word puzzles, crosswords,  
 sudoku or word finding games. 
Give yourself permission to focus on one thing at a time. 
Use a GPS unit if you have trouble with driving directions. 
Choose only activities that are important to you and allow yourself plenty of time to  
complete tasks so as to reduce stress. 
Consider use of relaxation techniques such as meditation or yoga. 
Maintain some form of regular exercise (this does not need to be strenuous). 
Don’t beat yourself up for not remembering things as you used to be able to before  
chemotherapy. 
Tell your family and friends you may need help remembering things and ask for their  
patience and support. 
Be aware that your reading retention may change during and after chemotherapy. This  
may affect your study habits or test taking ability.  
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When asked what information they would have liked to receive once they began to 
experience cognitive changes, participants acknowledged the desire for “someone regularly 
to ask them” if they were experiencing any difficulty with memory as a “part of the 
assessment”.  Participants suggested that the educational content described above could be 
reinforced throughout treatment. They also wanted reassurance that CRCI would resolve. 
Focus group participants noted that CRCI might not resolve and agreed that educational 
content should be carefully designed so as not to mislead.  The recommendation was to 
include a statement such as “many women experience improvement in memory and thinking 
over time”. Participants also wanted to be kept informed about any information on effective 
interventions.  
Exemplars 
 Interviews with two participants in particular yielded a very complete description of 
the experience of CRCI. The two exemplars that follow are drawn from those two interviews 
in which both participants volunteered information about almost all of the components of 
CRCI identified during the study. Pseudonyms were used to maintain confidentiality.  
 Exemplar 1. Prior to her breast cancer diagnosis, Rachel, a woman in her 40’s, left 
bedside nursing to become a full time homemaker and do the bookkeeping for the family 
business.  During chemotherapy, she described her frustration at not remembering her 
rationale for data entry.  She noted that she experienced similar issues when she was 
pregnant. She also described significant difficulty remembering names and maintaining 
social relationships. When introduced to a Director of Music candidate for her church she 
told the candidate and his wife up-front that she would not be able to remember their names.  
Later she felt she had been rude, but didn’t want to expend the social energy to explain her 
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situation that early in the relationship.  Rachel said that the cognitive changes were 
exacerbated by fatigue.  She was surprised by how draining social interaction could be, due 
to the difficulties in having conversations with word-finding issues and trouble focusing on 
the verbal and nonverbal cues in order to respond appropriately. A sample from Rachel’s 
interview follows: 
I do the family business book work and I like to be able to go down there and 
understand what I’m doing and be able to come back a week later and understand 
what I had done the week before. When I was pregnant [it feels like….],just like 
when I was in therapy (chemotherapy) at the end of the year when I’m going through 
the books again I’m like…why did I do this? Why did I put that and enter it this way? 
I have no clue! And it was the same thing going through the book work this year ….I 
don’t think it was quite as bad but it was just like...ok…I don’t know….you know I 
can’t tell you why, [decreased performance]  I… but a lot of it too, it’s just….in 
functioning, but when I’m tired it gets worse [other physical factors]. The fatigue is 
really…... Just yesterday I was at a friend’s house and ….I have to take a power nap, 
in the middle of the day or ….and I didn’t get that. And in trying to talk to her, one 
thing that I realized is that the energy required in interpersonal relationships is a 
whole lot more than I ever imagined. So talking, I can function at home but to get out 
with people where I am required to read their emotions or read…you know just that 
whole….I don’t think we realize how much energy we put into interpersonal 
relationships and when all of your energy is put into trying keep up with the 
conversation and making sure you’re acting appropriately? It’s like I’m exhausted. So 
after talking with somebody for awhile I start losing words [trouble with word 
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finding]. I can’t finish my thought. And I’m a fairly verbal person..…sometimes the 
words just don’t come.  
Exemplar 2. One of the younger participants particularly was distressed over the 
residual effects on cognition. Emily is only 26 years old and she feels like she lost 4 months 
of her life during chemotherapy. She continues to experience issues with short term memory 
and directional sense. Emily describes her experiences as follows:  
After chemo everything is sort of foggy. I keep making the joke to my husband that 
this is a whole new experience for me, Spring in this city, because I slept through last 
Spring. And I really do not remember much of those four months. It’s very foggy. 
Since then I don’t think I realized how much of a fog I was walking around in. A lot 
of that’s starting to clear, but I do find that it’s extremely hard to concentrate for very 
long at all. I can concentrate in short bursts of 20 to 30 minutes tops. And then I’m 
just thinking about a million things, sort of have drifted and I find it’s a lot harder to 
be as efficient at work as I was before [“lack of focus”]. I was always very organized 
and worked very efficiently, and I have a hard time being that way now [decreased 
performance]. I have to write things down in 3 or 4 places because I’ll forget it and 
can’t remember where I wrote it down [deficits in short term memory]. I get lost a lot 
easier driving [decreased executive function]. I have two GPS units and I typically 
take printed directions with me now also and I could not find where I was going to a 
meeting this morning. Forty-five minutes later I finally figured out where I was 
supposed to be. And at that point I had missed the meeting. I find that I get sort of 
confused about what word I’m trying to use [trouble with word finding]. I sort of feel 
like my grandmother who has Alzheimer’s ….it’s like…I sit there and have a 
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conversation and neither one of us can find the correct word [“it feels like…”]. So 
you know I just find that everything is a little more of a struggle to remember and to 
focus and to concentrate in general. I have to concentrate a lot harder to accomplish 
what I used to be able to do sort of easily.  
 Information provided in the exemplars highlights issues with word finding, 
attention/concentration, memory, and difficulty with driving as well as the coping strategies 
of writing things down and taking naps during the day to refresh mental clarity. Participants’ 
quotes demonstrate some of the difficulties with verbal expression and social interaction. The 
additional effort needed to accomplish day-to-day tasks is evident. 
Summary 
 The purpose of this qualitative descriptive study was to provide an in-depth 
description of the experience of CRCI for women with breast cancer. Specific aims of the 
study were to: 1) Describe the experience of CRCI for women with breast cancer who have 
received chemotherapy treatments; and 2) Identify information about CRCI that women 
would find useful prior to initiation of chemotherapy and following the onset of CRCI. The 
study purpose and aims were achieved by analyzing the data resulting from the in-depth 
interviews and focus group.  A rich description of the experience of CRCI was obtained, 
including information about how women cope with CRCI and recommendations for 
education. The three research questions were answered as follows.  
Research question 1: how do women who have received chemotherapy for breast 
cancer describe the experience of CRCI?. Participants described the experience of CRCI as 
frustrating and provided details about deficits in short term memory, trouble with word 
finding, lack of focus and decreased executive function, and negative impact on performance. 
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Half of the women complained of difficulties with reading and driving. Other physical 
factors were described including residual fatigue, clumsiness/decreased balance, and 
neuropathy. The trajectory of CRCI was variable. Most of the women described 
improvements in cognitive function over time with the exception of word finding. 
Participants shared a number of coping strategies including: writing things down, the 
importance of support and validation, depending on others, taking on one task at a time, and 
giving oneself permission to make mistakes. Younger women made requests for age-matched 
support. Interventions that were recommended included exercise, mind stimulation, getting 
enough rest, meditation/yoga, and nutrition.   
Research question 2: what information about CRCI would women who have received 
chemotherapy for breast cancer have found helpful prior to the initiation of treatment?. 
Participants wanted to know about CRCI prior to initiation of chemotherapy. The need for an 
individualized approach to education was stressed, including an assessment of preferred 
learning styles and a selection of type and volume of educational materials to meet the need 
for information. Participants desired interaction with a HCP who has expertise in education, 
was not rushed, and who, ideally, had personal experience with cancer and cancer treatment. 
The women noted the need for education for their family members. Recommendations were 
made for the educational content to be concise and free of medical jargon. Any information 
on incidence, recovery, and interventions was strongly desired.  
Research question 3: what information about CRCI would women with breast cancer 
have found helpful once changes in cognition are experienced?. Participants stressed the 
need for on-going assessment of CRCI by HCPs as well as reinforcement of education about 
CRCI throughout therapy and follow-up. Reassurance of recovery and any information on 
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interventions was requested. The following chapter contains a discussion of the research 
findings, conclusions, and recommendations for future research.  
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Chapter 5 
Discussion, Conclusions, and Recommendations for Future Research 
Discussion  
The study results provide evidence of self report of changes in cognitive function 
across a number of domains, including attention and concentration, short term memory, 
verbal memory, motor and executive function. Participants’ complaints of lack of focus and 
inability to concentrate are examples of changes in the attention and concentration domain.  
Short term memory deficits included the inability to remember the content of conversations 
or various tasks to be done and frequently losing objects such as keys and cell phones.  
Decreased verbal memory was described as inability to remember individuals’ names and 
pervasive difficulty with word finding.  Motor function was impaired for some participants 
who complained of changes in coordination and balance. Several examples of decreased 
executive function were reported such as difficulty with the steps involved in refueling a 
vehicle, paying the bills, or making out a grocery list.  
Information gleaned from the in-depth interviews was consistent with the research of 
Downie et al. (2006), i.e., complaints of changes in short term memory, concentration, verbal 
fluency and word finding, processing speed, executive function; change in ability to 
multitask, and trouble driving due to decreased sense of direction and trouble with 
concentration, memory and processing speed. Consistency also was seen between the results 
of the current study and the work conducted by Thielen (2008), i.e.,trouble remembering 
names, returning to the workplace, driving, impaired sense of direction, and remembering 
how to get to familiar places, and Boykoff et al. (2009), i.e., trouble with word finding, 
decreased processing speed, and diminished ability to read complex books; use of calendars 
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and post-it notes as well as some social withdrawal. Congruence with results discussed by 
Mulrooney (2007) also was noted (keeping a calendar, writing lists, dependence on family 
for assistance with memory).  
 Participants acknowledged the importance of validation of CRCI by both HCPs and 
family members. This need for validation may be congruent with the phenomenon of 
participants’ self-report of cognitive changes being more accurate than the results of current 
objective measures of cognitive function. Participants expressed frustration at the lack of 
validation of cognitive changes by family members but acknowledged that the changes 
participants perceived might not be noticeable to others. This hypothesis is consistent with 
that of Jacobs et al. (2007) who noted subjective measures may be sensitive to smaller effect 
sizes than those of available objective measures. Support of family, friends, and coworkers 
was noted to be very important to successful coping and included assistance with memory as 
well as patience and understanding concerning cognitive changes. Age-matched support was 
desired by younger participants due to the differences in issues they faced as a result of 
cancer and chemotherapy, such as fertility and finding a mate.  
 Responses to the demographic questionnaire yielded information about anxiety, 
depression, fatigue, and trouble sleeping. Further information about residual fatigue was 
obtained during the interviews as was information about past and current neuropathy and 
complaints of decreased balance and coordination (see Table 6). Notably, 17 of the 18 
participants reported one or more symptoms in addition to CRCI. Fatigue was the most 
commonly reported symptoms (n = 10), followed by trouble sleeping (n = 8), neuropathy (n 
= 8), anxiety (n = 7), and depression (n = 6).  
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 Fatigue and sleep disturbance are two of the most commonly reported symptoms for 
cancer survivors (Beck, Dudley, & Barsevick, 2005) and sleep disturbance is a common 
menopausal symptom. The majority of participants reported experiencing fatigue during 
chemotherapy (72%) and 55% continued to complain of residual fatigue at the time of the 
interviews. Similarly, 44% of the sample acknowledged trouble sleeping.  
Neuropathy is commonly experienced by survivors who receive a taxane as a 
component of chemotherapy (Taxol®, Taxotere®). Seventeen participants received a taxane, 
one of whom received both Taxol® and Taxotere®. One woman could not remember the 
names of the agents used for her chemotherapy regimen. Slightly less than half of the 
participants noted neuropathy (44%) during treatment and 27% mentioned residual effects.  
These findings are consistent with the results of a recent secondary analysis of a data 
set for women with ovarian cancer. The secondary analysis was conducted to explore the 
potential relationship between receiving chemotherapy and complaints of memory problems 
(Myers, Sousa, Donovan, 2010). Women with ovarian cancer who had received 
chemotherapy (n = 638) were statistically significantly more likely (t(82.70) =   -3.12, p < 
.01, mean difference = -1.04, CI from -1.7 to -.38) to complain of memory problems than 
whose who had not received chemotherapy (n = 68). Regression analysis demonstrated that 
fatigue (ß = .18, p < .01) neuropathy (ß = .07, p < .05) and sleep disturbance (ß = .16, p < 
.01) were significant predictors for complaints of memory problems in addition to mood 
swings (ß = .23, p < .01).  Further exploration of the potential relationships between fatigue, 
neuropathy, trouble sleeping, and CRCI is warranted. Given the potential predictive nature of 
fatigue, neuropathy, and trouble sleeping for complaints of memory problems, residual side 
effects may be predictive of long-term CRCI.  
  
105
 
 Fatigue has been noted to be a potentially confounding variable for CRCI (Nail, 
2006) yet studies in which confounding variables have been controlled still yielded the 
independent presence of cognitive changes (Ahles et al., 2002). Results from the secondary 
analysis described above in conjunction with results from the present study lend support to 
the need for further examination of a moderator effect of fatigue on CRCI.  
 Clumsiness and/or issues with balance and coordination were reported by 27% of the 
sample. This finding was not mentioned in the qualitative work performed by Theilen, 
Mulrooney, or Boykoff. A comparison was made between the participants who experienced 
neuropathy (n = 8) and those complaining of balance and coordination issues (n= 5) (see 
Table 6). One participant was common to both groups and did note residual neuropathy (right 
great toe). This result was surprising as neuropathies can contribute to decreases in motor 
coordination (complaints of dropping items) or issues with gait (complaints of tripping or 
stumbling). The lack of commonality between the two groups may indicate the presence of 
an unidentified factor that contributes to balance and coordination issues.  Further work may 
be warranted in this area of investigation.  
 Other confounding factors mentioned in the literature include anxiety and depression. 
Participants were asked to report whether they were currently experiencing either of these 
states on the demographic questionnaire. Seven participants documented anxiety (38%) and 6 
reported depression (33%). Five participants noted both anxiety and depression (27%). 
Fatigue accompanied anxiety and depression for three participants (16%).  Four participants 
noted both depression and fatigue (22%).  Trouble sleeping was reported by 44% of the 
sample and occurred in conjunction with depression (16%), anxiety (16%), and fatigue 
(33%). Two patients reported all four symptoms (11%). In this study anxiety, depression, and 
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trouble sleeping were reported less frequently than fatigue. Some overlap among the four 
symptoms was noted, providing support for further analysis of concurrent symptoms. 
 Participants varied in the amount of distress related to CRCI they expressed during 
the interviews. The study was not designed to quantify levels of distress or to detect age-
related patterns related to the amount of distress described. However, study results in the 
literature indicate distress may be heightened for younger women who may be more 
perceptive of subtle changes in cognitive function (Cimprich et al., 2005). The two women 
who appeared to express the least amount of distress related to CRCI in this study were 51 
and 52 years of age. Future studies should include some rating of symptom distress related to 
cognitive changes.  
 Two participants related loss of employment to cognitive changes. One participant 
described significant changes in school performance during and after chemotherapy. The 
majority of participants was employed full time and did not report a change in work status 
since diagnosis of breast cancer.  Focus group participants validated reports of slower time 
frames to complete work-related tasks due to decreases in processing speed and difficulties 
with reading and comprehension.  These results are consistent with a recent qualitative study 
conducted by Munir, Burrows, Yarker, Kalawsky, and Bains (2010) where women reported 
poor concentration, memory problems, difficulties in thinking quickly, and issues with 
reading comprehension having an impact on their work performance. However participants 
in the Munir study felt cognitive effects were independent of fatigue.  
 The majority of participants acknowledged the importance of receiving information 
about CRCI prior to receiving chemotherapy, thereby reinforcing the need to educate about 
this potential side effect as a component of providing informed consent. Thirty-three percent 
  
107
 
of participants were informed about CRCI prior to therapy by a HCP.  This percentage is 
lower than that reported by Myers and Teel, where 44% of nurses educated patients and 
families about CRCI.  However in the current study three participants noted they received 
information about CRCI from their oncologist. Strides are in progress towards provision of 
much desired education, however further improvement is needed to meet women’s needs. 
 Participants expressed a desire to be informed of any intervention that could help 
improve their cognitive function. A number of potential interventional strategies are under 
study such as neurostimulants, exercise cognitive retraining (ClinicalTrials.gov, 2010), and 
biofeedback (J. Alvarez, Ed.D., Lake Erie Brain Performance Institute, LLC., personal 
communication, March 8, 2010).  Participants described a number of strategies used for 
coping with changes in cognitive function. These strategies are an important component of 
the educational content that should be provided to women with breast cancer prior to 
initiation of chemotherapy.  
 The desire to “give back” or to “find something positive” in the diagnosis and 
treatment of breast cancer was consistent with the literature regarding “finding meaning in 
the cancer experience (Lee, 2008; O’Connor, Wicker, & Germino, 1990). Four of the 
participants in this study shared a strong desire to help others through the experience and be 
an inspiration to women receiving chemotherapy.   
 During the course of recruitment for this study a number of women expressed an 
interest in participation, but were not eligible because of being longer than twelve months 
from completion of chemotherapy. These women expressed frustration at not being allowed 
to participate as they continued to self-report CRCI. The two key informants who were 
interviewed prior to data collection both recommended collecting data from women greater 
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than 12 months after completion of chemotherapy. All but three participants (16%) in the 
current study described experiencing some improvement in cognitive function over time with 
the majority noting improvement beginning within 1-2 months of completing therapy. A 
subset of patients (approximately 17-34%) may experience long-term cognitive changes after 
completion of chemotherapy (Ahles and Saykin, 2007). A logical next step to follow the 
current study would be to explore the experience of CRCI for women with breast cancer who 
are greater than 12 months from the completion of chemotherapy as the experience may vary 
as a factor of time.  
Contribution to Theory Development 
 The study results contribute to the development of the Revised Conceptual Model of 
Chemotherapy-Related Changes in Cognitive Function Based on the Theory of Unpleasant 
Symptoms (see Figure 1) (Myers, 2009). The model depicts fatigue, depression, and anxiety 
as concurrent symptoms and neurotoxicity as an associated toxicity.  Additionally anxiety 
and depression also are shown as psychosocial mediating factors. The model also depicts 
consequences of CRCI to functional ability.  Results of the current study provide support for 
the impact of CRCI on functional ability related to self-reported deficits for job and school 
performance.  Results of the current study suggest that the concurrent symptom of fatigue 
may require further evaluation as a potential moderating factor of CRCI in the model. The 
study results also suggest some support for the concurrent occurrence of fatigue, anxiety, and 
depression, and sleep disturbance.  The model has been updated to reflect these two revisions 
(see Figure 2). Prospective quantitative studies are needed to further examine these revisions 
to the model.  
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Figure 1. Revised Conceptual Model of Chemotherapy-Related Changes in Cognitive 
Function Based on the Theory of Unpleasant Symptoms. From “A comparison of the theory 
of unpleasant symptoms with the conceptual model of chemotherapy-related changes in 
cognitive function,” by J. S. Myers 2009. Oncology Nursing Forum, 36(1), E1-E10, 
Copyright 2009 by Oncology Nursing Society. Reprinted with permission. 
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Figure 2. Revised Conceptual Model of Chemotherapy-Related Changes in Cognitive 
Function Version 2 
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 The overarching study theme, Life with Chemobrain, and two of the primary themes, 
How I Changed, and How I Cope, reflect the consequences of CRCI on health-related QOL 
and alterations to functional ability. The third primary theme, How to Teach Me supports 
women with breast cancer’s desire to be provided with information about the phenomenon of 
CRCI.  This desire, as well as participants’ suggestions for interventional strategies, is not 
captured by the model referenced above.  However, the study themes provide a framework 
for enhanced understanding of CRCI and can be used to educate HCPs about the 
phenomenon (see Figure 3). The framework can be used to guide content to include 
information about the experience of CRCI, common coping strategies, and information 
important for inclusion in the development of an approach to patient/family education.  
Conclusions 
 Based on interviews with the women who participated in this study, women with 
breast cancer who self-report cognitive changes during and following chemotherapy 
described issues with short term memory, trouble with word finding, difficulty with focusing, 
reading, and driving. Women acknowledged the importance of support as well as validation 
of the experience by those close to them. Women who self-reported CRCI employed a 
variety of coping strategies including writing things down, depending on others to assist them 
with remembering important tasks and events, exercise, focusing on one task at a time, and 
giving themselves permission to make mistakes. Women described obtaining cognitive 
benefit from exercise and getting enough rest. Women also recommended mind stimulation, 
meditation/yoga and good nutrition. 
Women diagnosed with breast cancer wanted to know there was a potential for 
experiencing CRCI prior to initiating treatment with chemotherapy. Women wanted an  
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Figure 3. Life With Chemobrain Thematic Framework 
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individualized approach to education including an assessment of their preferred learning style 
and desired timing for receiving information.  Women preferred to receive information from 
an HCP who has demonstrated expertise in education and ideally would like involvement by 
an individual who is a cancer survivor. Women with breast cancer wanted a tailored 
approach to the volume of information provided and wanted to be able to choose the format, 
such as one-on one conversation, written materials, or a list of pertinent websites. Education 
content should include information on the incidence and duration of CRCI (once known), a 
description of the phenomenon, and recommendations for intervention (once known) and 
coping strategies. The need for education of family members (including both significant 
others and children) was emphasized by participants. 
 Women described wanting on-going assessment for changes in cognitive function 
while they were receiving chemotherapy. This assessment could be as simple as a question 
related to whether they were experiencing any changes in memory.  They recommended on-
going reinforcement of education about CRCI throughout and following the course of 
therapy.  
 Participant’s verbal responses to the semi-structured interview questions provided 
important information about the experience of CRCI and direction for development of an 
educational approach that would have been difficult to capture as a result of a quantitative 
survey. Live interviews offered the opportunity to further explore participants’ descriptions 
and to observe both manifest and latent behaviors. Direct interaction between the investigator 
and the participant allowed additional questions to be asked and facilitated detailed 
participant responses that survey techniques do not provide.                                                                                     
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Recommendations for Future Research 
 As expected, based on current standards of care for treating breast cancer, the 
majority of participants received an anthracycline (doxorubicin, Adriamycin®), 
cyclophosphamide (Cytoxan®) and a taxane (paclitaxel, Taxol®; docetaxel, Taxotere®; or 
paclitaxel protein-bound particles for injectable suspension, Abraxane®). These agents have 
been associated with oxidative stress and the release of proinflammatory cytokines, and thus 
potentially are associated with resultant changes in cognitive function. Further work in 
animal modeling is needed to confirm causality and mechanism of action related to CRCI. 
Results from this study support the need for further exploration of the relationships 
between fatigue, neuropathy, trouble sleeping and CRCI. The study results also support work 
in the area of examining the relationships between CRCI, neuropathy, clumsiness, and 
changes in balance and coordination.  Future prospective quantitative studies should include 
hierarchical regression analysis to further examine the potential moderating effect of fatigue 
on CRCI.  
Intervention studies are needed to identify strategies to prevent, minimize, or resolve 
CRCI. Areas of interest include exercise, cognitive retraining and nutrition (i.e. hydration and 
protein).  
Results from this study may be helpful in the development of self-report instruments 
to quantify CRCI. Current instruments such as the Functional Assessment for Cancer 
Therapy- Cognition (FACT-COG) do not contain items related to difficulties with reading or 
driving. Further work is needed to explore whether difficulties with reading and driving are 
seen in larger populations of breast cancer survivors, those greater than 12 months from 
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completion of chemotherapy, and survivors of other tumor types who have received 
chemotherapy.  
Participants’ requests for individualization of educational methods and specific 
recommendations for educational content should be incorporated into plans of care and 
appropriate educational materials developed. Pilot testing of educational methods and tools is 
needed to demonstrate success and patient satisfaction.  
A logical next step moving forward from the current study would be to conduct a 
similar study for women with breast cancer who are greater than 12 months from completion 
of chemotherapy. The experience of CRCI may differ based on the length of time since the 
completion of chemotherapy. Enhanced understanding of the CRCI trajectory may provide 
information necessary to identify individuals at high risk for CRCI as well as the 
development of appropriate interventions. Utilization of brief measurement tools such as the 
FACT-COG to further describe the sample would be of benefit, as would the use of tools to 
explore the level of distress and impact on quality of life related to CRCI. Revision of the 
demographic questionnaire used in the current study is recommenced to include a question 
related to recent surgical procedures in which general anesthesia was used. Ultimately, the 
research in this area needs to be expanded beyond women with breast cancer to include 
survivors of other tumor types. 
Implications for Nursing 
 The results of this study include an in depth description of the experience of CRCI 
and specific recommendations for the development of an educational approach and materials 
for women with breast cancer who will be receiving chemotherapy and their families. 
Oncology nurses are on the front-line for patient assessment, and patient/family education 
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about breast cancer, treatment, and related sequelae. Oncology nurses play an important role 
in obtaining informed consent prior to the initiation of therapy. Practical application of the 
study results will serve to validate the experience of CRCI for women with breast cancer and 
contribute to patient satisfaction with the delivery of care. Oncology nurse researchers should 
utilize the study results to support further nursing research in the area of CRCI.  
Personal Reflection 
 I learned a great deal during the course of conducting this qualitative, descriptive 
study. I was granted an opportunity to see the experience of coping with a diagnosis of breast 
cancer and learning to live with the changes in cognitive function resulting from the 
treatment through the eyes of 18 survivors. As they shared their stories and experiences with 
me I could sense their frustration with the health care system and their sense of loss related to 
changes in their lives. I learned that our present methods of patient education are not meeting 
the needs of breast cancer survivors, and likely not survivors of other types of malignancies. 
In spite of the challenges around the time constraints of providing patient care in the current 
environment, we need to creatively craft solutions to allow staff the time and development of 
expertise to individualize educational plans of care. 
 On a more personal note, I confirmed the fact that I miss regular patient contact and 
find that aspect of conducting research intensely satisfying. With the help of the expert 
reviewers on the study team, I validated the ability to move outside of my typical linear mode 
of approaching the world and was able to begin to develop the skills necessary to be 
successful at qualitative research methodology. One such skill is the ability to synthesize 
participants’ descriptions into meaningful categories and then further personalize the study 
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results into themes that capture the essence of the experience being described while 
remaining true to participants’ words.  
I was troubled by the fact that many of the participants hoped I would be able to tell 
them specific information regarding expectations for improvement in cognitive function and 
a time frame for returning to baseline performance. I found this painful and worried that I 
was taking their time to learn more about CRCI without being able to provide them with 
effective interventions or what they so desperately wanted to hear, i.e., that CRCI will 
eventually completely resolve. As a result of conducting this study I am even more 
committed to continuing to investigate CRCI. My next step is to disseminate these study 
results, to be followed by the development of future research to continue to add to the body 
of knowledge about CRCI.  
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Appendix B 
 
LETTER TO HEALTH CARE PROFESSIONALS: DESCRIPTION OF THE STUDY 
 
Dear Oncologist or Oncology Nurse, 
 
I am seeking your help to recruit participants for a research study.  As part of my 
doctoral dissertation research, I am conducting a qualitative study designed to provide an in-
depth description of the experience of chemotherapy-related cognitive impairment 
(CRCI) for women with breast cancer.  Enclosed are the study synopsis and eligibility 
criteria, as well as a flyer providing a description of the study and my contact information. 
After reviewing the synopsis and flyer, if you have patients in your practice that are 
eligible, I am asking you to let them know about the study and ascertain interest.  Please 
provide interested eligible women with the flyer and my contact information. I would be 
happy to talk with you by phone or in person if you have questions or would like more 
information.  I hope you will encourage any eligible women to consider participation.  If you 
are willing, I can provide copies of the flyer for your waiting area and/or staff to use in 
talking with patients 
The desired outcomes for this study are to gain a better understanding of the patient 
experience and guide development of appropriate educational tools to use with women about 
to receive chemotherapy and for those who begin to report changes in cognitive function.  I 
appreciate your time and consideration on this matter. 
Warm regards, 
 
Jamie S. Myers RN, MN, AOCN 
913-449-5996 (cell) 
jmyers@kumc.edu  
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Appendix C 
Study Synopsis 
Specific aims of the study are to:  
• Describe the experience of CRCI for women with breast cancer who have received 
chemotherapy treatments 
• Identify information about CRCI that women would find useful prior to initiation of 
chemotherapy and following the onset of CRCI 
 
Inclusion Criteria 
• Adult women (aged 18 or older) 
• Diagnosed with any stage of breast cancer 
• Within 6-12 months of completing standard-dose chemotherapy 
• Previous or current hormonal therapy is acceptable 
• Self-report changes in cognitive function (such as changes in ability to concentrate, 
remember, or focus on tasks; difficulty with finding the right word or phrase or doing 
mathematical calculations; or problems with sense of direction when driving) 
• Able to read, write, speak, and understand English    
 
Exclusion Criteria 
• Evidence of central nervous system metastases 
• History of mental illness, dementia, or Alzheimer’s disease  
• Currently taking psychotropic medications (with the exception of benzodiazepines or 
selective serotonin uptake inhibitors prescribed for the treatment of anxiety or 
depression).   
 
About 15 women will be asked to participate in a semi-structured in-depth interview.  
 
All participants will be asked to complete a demographic questionnaire including information 
about age at diagnosis, menopausal status, stage of disease, regimen and duration of therapy. 
 
Willing participants may be contacted to participate in a focus group to check for agreement 
with the research findings and elicit suggestions for revision.   
 
There is no cost for participation in the study and no reimbursement to patients for 
participation.   
 
Human Subjects Committee approval has been obtained through the University of Kansas 
Medical Center (KUMC).   
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Appendix D 
Flyer 
Are you a woman who has experienced changes 
in thinking or memory since receiving 
chemotherapy for breast cancer? 
 
If so, (and you are within 6-12 months of completing chemotherapy) you are invited 
to take part in an interview to describe your experience.  I am an oncology nurse who is 
interested in learning more about the changes in thinking or memory (cognitive function) that 
some women with breast cancer experience with chemotherapy.  The purpose of this study is 
to learn more about this experience in order to help doctors and nurses to better understand 
what women may go through and to develop some useful educational materials.     
Participation in this study would involve: 
• Completing a questionnaire (about 10 minutes) 
 
AND 
 
• Taking part in an interview with me (about 60 minutes) 
• If you are willing to be contacted again in the future, you may be asked to take part in 
a small group interview with me and 5-8 other women who have/had breast cancer 
and chemotherapy and report some changes in thinking or memory 
 
To be eligible for this study you must be: 
 
• A woman with a history of breast cancer 
• Within 6-12 months of completing chemotherapy 
• Age 18 or older 
• Able to write, speak, read, and understand English 
 
If you would be interested in participating, or learning more about this research study, please 
contact me:   
 
Jamie Myers RN, MN, AOCN 
913-449-5996 
jmyers@kumc.edu   
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Appendix E 
Demographics Questionnaire 
Date: ______________ 
1. How old were you when you were diagnosed with breast cancer? ____ 
2. How old are you now? ___ 
3. What is your marital status? 
___single 
___ married 
___ divorced 
___ widowed 
___ in a relationship  
4. Has your marital status changed since you were diagnosed with breast cancer?  
___ yes ___ no 
If so, how? 
___ married 
___ separated 
___ divorced 
___ widowed 
___ in a relationship 
___ other (please describe) 
 
 
 
  
141
 
5. What is your ethnicity? 
 ___ White, non-Hispanic  ___ Native Hawaiian/Pacific Islander 
 ___ Black, non-Hispanic  ___ Two or more races, non-Hispanic 
 ___ American Indian   ___ Hispanic/Latino 
 ___ Asian    ___ Other (please describe) 
 
6. What is was your menopausal status before you received chemotherapy? 
 ___ Pre-menopausal (still menstruating) 
 ___ Peri-menopausal (greater than 3 months and less than 6 months since last  
  menstrual period 
 ___ Post-menopausal (no longer menstruating, greater than 6 months since last  
  menstrual period, or post hysterectomy) 
7. What is was your menopausal status now? 
 ___ Pre-menopausal (still menstruating) 
 ___ Peri-menopausal (greater than 3 months and less than 6 months since last  
  menstrual period 
 ___ Post-menopausal (no longer menstruating, greater than 6 months since last  
  menstrual period, or post hysterectomy) 
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8. What is your employment status? You may check more than one if appropriate. 
 ___ full time home-maker 
 ___ part time home-maker 
 ___ no longer able to function as a home-maker 
___ employed full time  
___ employed part time  
___  retired   
___ on medical leave from my job 
____ not presently working  
 
 
9. Has your employment status changed since you were diagnosed with breast cancer?  
 ____ yes ___ no 
 If so, how? 
 ___changed jobs  ___missed promotion 
 ___lost job   ___went part-time 
 ___ retired   ___ other (please describe) 
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10. What is your highest level of education? 
 ___ grade school 
 ___ high school 
 ___ college 
 ___ graduate school 
11. What was the stage of your initial diagnosis with breast cancer? 
 ___ Stage 1   ___ don’t know 
 ___ Stage 2 
 ___ Stage 3 
 ___ Stage 4 
12. When was your last chemotherapy for breast cancer (approximate month and year)? 
 
13. What were the names of the chemotherapy drugs you received to treat your breast  
 cancer? 
 ___ 5FU (fluorouracil) ___ methotrexate 
 ___ adriamycin  ___ taxotere 
 ___ cytoxan   ___  other (please describe) 
 ___ taxol   ___ don’t know 
 ___ herceptin 
 ___ epirubicin 
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14. How often did you receive your chemotherapy? 
 ___ every 3 weeks 
 ___ every 2 weeks 
 ___ every 1 week 
 ___ other (please describe) 
 
 
15. Over how many months (or cycles) did you receive chemotherapy? 
 
 
 
16. Have you received hormonal therapy to treat your breast cancer (such as Tamoxifen,  
 Nolvadex, Femara, Letrozole, Arimidex, Anastrozole, Exemestane, Aromasin,  
 Goserelin, Zoladex)?  
 ___ yes 
 ___ no 
 If yes, are you currently receiving hormonal therapy? 
 ___ yes 
 ___ no 
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17. Are you having any symptoms related to menopause? 
 ___ hot flashes 
 ___ trouble sleeping 
 ___ feeling irritable 
 ___ weight gain 
 ___ other (please describe)  
 
18. Are you experiencing any of the following? 
 ___ anxiety 
 ___ depression 
 ___ fatigue 
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Appendix F 
Interview Guide: 
 
Primary Questions: 
1) How would you describe your experience with changes in thinking or memory during  
chemotherapy?  
 
 
2) What information would you have found helpful prior to starting chemotherapy? 
 
 
3) What information would you have found helpful once you began to notice changes in your  
thinking or memory? 
 
 
4) Is there anything else you would like to share about your experience? 
 
 
Potential Probes 
a. When did you first notice the changes in thinking or memory? 
b. Did the changes get worse or better during therapy? 
c. Have you noticed any changes or improvement after therapy was completed? 
1. If so, tell me about the sequence of events (time-line) 
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d. What did you find that made your thinking ability or memory better? 
e. What did you find that made your thinking ability or memory worse? 
f. What did you find that helped you cope with the changes in thinking ability or memory? 
g. What impact have these changes had on your relationships (family/friends/co-workers). 
h. What impact have these changes had on your job (or ability to function day-to day). 
i. How have these changes affected other aspects of your life? 
j. Did you receive any information about changes in thinking or memory prior to receiving  
chemotherapy? 
k. When would have been the best time to receive information about changes in thinking or  
memory? 
l. Who would you have liked to provide you with this information? 
  
 
